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I. Abstracts 
I.1. Abstact 
 
In neoplastic diseases the tumor stroma and especially tumor-associated macrophages 
(TAMs) play an important role in tumor growth and progression. TAMs exhibit an intensive 
cross-talk with tumor cells resulting in the promotion of angiogenesis and the inhibition of 
local protective immune responses in certain tumor entities. Therefore, TAMs are a potential 
target for tumor therapy. 
Here it was shown that intravenously applied intracellular bacteria like Salmonella and 
Shigella primarily target TAMs. To exploit this feature a growth attenuated Shigella strain 
with the capacity to induce apoptosis in macrophages was designed. Shigella are invasive 
bacteria that penetrate the colonic tissue and initiate an acute inflammation. In macrophages, 
Shigella rapidly induces caspase-1 processing and apoptosis via the virulence factor IpaB. By 
genomic deletion of the aroA-locus a metabolically attenuated strain defective in intracellular 
growth but with retained capacity of infection, cell-to-cell spread, caspase-1 processing and 
apoptosis induction in macrophages was designed. It was shown that this strain primarily 
targets TAMs in 4T1 cell induced and transgenic MMTV-HER2/new breast cancer models. 
Shigella were almost exclusively found intracellularly, whereas growth attenuated Salmonella 
were also found extracellularly at late time points. The metabollically attenuated Shigella 
strain with retained virulence, but not avirulent Shigella strains, was able to activate caspase-1 
and induce apoptosis in TAMs at all time points (4 h, 6 h and 7 d p.i.) in both breast cancer 
models. This unrestricted apoptosis induction translated into a substantial, long-lasting and 
highly significant reduction of TAMs number (up to 70 %) in both models. In contrast, 
Salmonella could only induce apoptosis in TAMs at early time points (6 h p.i.) and failed to 
reduce TAMs in both models. 
In the 4T1 model, the effect on tumor size was monitored and treatment of the mice with the 
attenuated Shigella strain resulted in a complete block of tumor growth. Finally, Shigella 
primarily infected the macrophage fraction, activated caspase-1 and induced apoptosis in cells 
derived from a human ovarian carcinoma ex vivo.  
Taken together, this data suggests that growth attenuated intracellular bacteria capable of 
inducing apoptosis in TAMs are a promising therapeutic option for certain cancer diseases 
where TAMs have a proven role for tumor growth or progression. 
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I.2. Zusammenfassung 
 
Tumorstroma und Tumor-assoziierte Makrophagen (TAMs) spielen in neoplastischen 
Erkrankungen eine wichtige Rolle im Bezug auf Tumorwachstum und Progression. In einigen 
Krebsarten besteht zwischen den Tumor-assoziierten Makrophagen und den Krebszellen eine 
intensive Interaktion, welche zu vermehrter Angiogenese und zur Unterdrückung lokaler 
Immunantworten führt. Aus diesem Grund stellen TAMs einen vielversprechenden 
Angriffspunkt für eine Krebstherapie da. 
In dieser Arbeit wird gezeigt, dass intrazelluläre Bakterien wie Salmonella und Shigella 
hauptsächlich TAMs im Tumorgewebe infizierten. Um dieses Verhalten näher zu 
untersuchen, konstruierten wir einen im Wachstum abgeschwächten Shigella Stamm, welcher 
jedoch noch die Fähigkeit hat, Apoptose in Makrophagen zu induzieren. Shigellen sind 
invasive Bakterien, die in das Darmgewebe einwandern und dort eine massive Inflammation 
induzieren. Intrazelluläre Shigellen aktivieren Caspase-1 und induzieren dadurch Apoptose in 
Makrophagen durch den sekretierten Virulenzfaktor IpaB. Durch eine Deletion des 
genomischen aroA-Gens, wurde ein Shigella Stamm konstruiert, der Defekte im 
intrazellulären Wachstum aufweist. Dennoch war dieser Stamm noch fähig eukaryotische 
Zellen zu infizieren, sich interzellulär fortzubewegen, Caspase-1 zu aktivieren und Apoptose 
in Makrophagen zu induzieren. Es wurde gezeigt, dass dieser Shigellen Stamm nach i.v. 
Injektion hauptsächlich die TAMs im 4T1-induzierten und transgenen MMTV-HER2/neu 
Brustkrebsmodel infizieren. Diese attenuierten Shigellen wurden im Tumorgewebe 
hauptsächlich intrazellulär detektiert, im Gegensatz dazu wurden attenuierte Salmonellen zu 
späten Zeitpunkten (7 d p.i.) auch extrazellulär im Tumorgewebe aufgefunden. Der 
metabolisch aber nicht in der Virulenz attenuierte Shigella Stamm konnte in beiden 
Brustkrebsmodellen zu allen Zeitpunkten (4 h, 6h and 7 d p.i.) Caspase-1 in TAMs aktivieren 
und Apoptose induzieren. Diese Apoptose führte in beiden Brustkrebsmodellen zu einer 
langandauernden und hoch signifikanten Reduktion der TAMs-Anzahl (bis zu 70 %). Im 
Gegensatz dazu konnten Salmonellen nur zu frühen Zeitpunkten (6 h p.i.) Apoptose in TAMs 
induzieren und dies führte in beiden Modellen zu keiner Reduzierung der TAMs-Anzahl.  
In dem 4T1-induzierten Tumormodel wurden die Mäuse mit dem attenuierten Shigella Stamm 
behandelt, was zu einer kompletten Blockierung des Tumorwachstums führte, dies traf aber 
nicht für den avirulenten Stamm zu. Darüberhinaus infizierte Shigella hauptsächlich die 
Makrophagen Fraktion eines Ovarkarzinoms ex vivo und induzierte in diesen Zellen Caspase-
1 Aktivierung und Apoptose. 
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Zusammenfassend zeigen diese Daten, dass im Wachstum attenuierte intrazelluläre Bakterien 
dazu fähig sind Apoptose in TAMs zu induzieren. Dadurch werden sie zu einem 
vielversprechenden Therapeutikum zur Behandlung von betimmten Krebserkrankungen, bei 
denen TAMs eine erwiesene Rolle im Tumorwachstum und der Tumorprogression spielen. 
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II. Introduction 
II.1. Bacterial tumor therapy 
 
In 1868, the German physician W. Busch intentionally infected a cancer patient with 
erysipelas hoping for tumor regression. Although rapid tumour shrinkage occurred, the patient 
died nine days after infection. In 1883, after identifying Streptococcus pyogenes as the 
causative agent of erysipelas, F. Fehleisen reported tumor regression in cancer patients upon 
treatment with live streptococci1. In 1891, the American surgeon W.B. Coley also noted the 
cure of cancer by a severe Streptococal infection2. Since then, other bacteria have been shown 
to infiltrate, replicate and then preferentially accumulate in tumors1,3.  
As tumors or metastases develop, they stimulate angiogenesis to promote the formation of 
new blood vessels. This abnormal vascular supply found in tumors is an important factor for 
bacterial colonisation of the tumor. However, the newly formed vessels are highly 
disorganised with incomplete endothelial linings and blind ends, resulting in sluggish blood 
flow, leakiness for particles and inefficient delivery of nutrients and oxygen to the tumor or 
metastases. This leads to multiple regions of hypoxia (<1% oxygen or 0–20 mmHg) and 
anoxia within the tumor4,5. The combination of poor nutrient delivery and oxygen starvation 
results in non-proliferating hypoxic/anoxic cells within tumors and promotes growth of 
anaerobic and facultative anaerobic bacteria. Areas of necrosis provide nutrients such as 
purines to further promote the growth of the bacteria. It is also believed that these areas with 
low oxygen and high interstitial pressure are an immunological sanctuary, where bacterial 
clearance mechanisms are inhibited4,5.  
This leads to the use of bacteria as vectors to target therapeutic gene expression to tumors and 
its usefulness in cancer gene therapy. Any bacterium suitable for use as a tumor-targeting 
vector must possess several features. It must be genetically tractable, non-pathogenic or 
attenuated so it is well-tolerated by the host, exhibit accumulation within tumors, be motile 
and be susceptible to antibiotics so it can be cleared from the body following gene delivery. 
Thus, the ideal bacterial vector could be administered systemically, deliver its therapeutic 
payload specifically to the primary or secondary tumor and not to normal tissues thereby 
eliminating unwanted side effects6. Once in the tumor, the motile bacteria should then 
disperse throughout the tissue, overcoming the diffusion and distal pressure gradients and 
deliver the therapeutic agents to all regions of the lesion. Motility is a major advantage that 
bacteria have over viral vectors, as viruses exhibit a lack of specificity for tumors and, when 
they are present, they are poorly distributed throughout the tumor mass (often confined to 
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peri-vascular regions). In addition, the metabolically active bacteria should replicate and 
continue to produce active agents whilst the tumor remains infected, thus amplifying a low 
dose to an effective level only within the target tumor6. 
 
II.1.1. Extracellular and intracellular bacteria in tumor therapy 
For some extracellular bacteria, such as genetically modified obligate anaerobe Clostridia, an 
anti-tumor effect was observed7. Other extracellular bacteria such as E. coli accumulated in 
tumor tissue, induced some inflammatory responses, but failed to confer protection8. Also 
facultative intracellular bacteria such as Salmonella have been used for tumor therapy and 
their intratumoral accumulation was studied using different technologies, albeit beyond 
cellular resolution9,10. In most syngenic experimental models a moderate therapeutic effect 
was shown, whereas more pronounced efficacy has been seen in xenograft models10-13. It was 
speculated that the induction of an inflammatory response is mediating the anti-tumor effect. 
Intracellular bacteria have been shown to target tumors, albeit with modest therapeutic 
efficacy14. As an example, i.v. injected Salmonella and intratumorally injected Shigella 
induced necrosis in a colon cancer model (which is normally not associated with high 
numbers of macrophages), but protection was only reached after depletion of neutrophils15.  
Besides exerting a toxic effect, intracellular bacteria can deliver DNA into eukaryotic cells16. 
Therefore, intracellular bacteria could be employed to deliver toxins or prodrug converting 
enzymes directly into tumor cells. In contrast to the therapeutic approaches with extracellular 
bacteria, the efficacy of tumor therapy with intracellular bacteria is dictated by the fraction of 
tumor cells which are infected. However, no information on the distribution of intracellular 
bacteria in different tumor cell types is available. In this work the tumoral distribution of 
intracellular bacteria such as attenuated Shigella should be quantitatively determined after i.v. 
application. Importantly, phagocytic cells such as macrophages or dendritic cells are the 
primary target of intracellular pathogens. Within the macrophage, bacteria such as Salmonella 
and Shigella can survive using distinct virulence mechanisms and can induce apoptosis of the 
infected macrophages through activation of caspase-1 mediated by IpaB (Shigella) or SipB 
(Salmonella)17,18. In contrast to the physiological situation, the phagocytic defects of tumor-
associated macrophages might block the uptake of intracellular bacteria and favor the direct 
infection of tumor cells. 
To analyse the distribution of Salmonella and Shigella after i.v. application in tumors with 
high numbers of macrophages, we quantitatively determined the bacterial counts of bacteria in 
II. Introduction  18  
the extracellular space or within tumor cells, distinguishing between the macrophage and non-
macrophage fraction. 
 
II.2. Shigella flexneri 
 
Members of the genus Shigella are gram-negative facultative anaerobes that belong to the 
family Enterobacteriaceae. The  genus is divided into four species: Shigella flexneri,  
Shigella boydii, Shigella sonnei and Shigella dysenteriae. These species are further divided 
into serotypes based on biochemical differences and variations in their O-antigen. Based on 
this classification scheme, Shigella flexneri is divided into 13 serotypes19. 
 
II.2.1. Pathogenesis of Shigella flexneri 
S. flexneri is highly infectious, requiring as little as 100 cells to cause disease in adult 
volunteers20. This low infective dose is in part attributed to S. flexneri`s ability to survive the 
low acidity of the host`s stomach, via an up-regulation in acid resistance genes21. Once S. 
flexneri reach the colon, they begin to invade the mucosa, penetrating, replicating within and 
spreading between the mucosal epithelial cells. This behaviour and the subsequent 
inflammatory response of the host destroy the colonic epithelial layer generating the clinical 
symptoms of shigellosis (Fig. 1)22. 
 
 
Figure 1: Pathogenesis of Shigella flexneri19 
1. Lumenal bacteria invade the colonic epithelial layer by three known mechanisms. S. flexneri can 
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manipulate the tight junction proteins, allowing paracellular movement into the sub-mucosa. 
2. PMN cells recruited by IL-8 and IL-1β produced in response to S. flexneri invasion create gaps between 
epithelial cells. 
3. Endocytic M cells transcytose bacteria, releasing them into an intraepithelial pocket filled with B and T 
lymphocytes and macrophages 
4. Macrophages phagocytose the bacteria. S. flexneri escapes the phagosome and induces apoptosis. The 
apoptotic macrophages release IL-1β. 
5. Submucosal S. flexneri contact the basolateral membrane of epithelial cells, activating secretion of 
proteins through their type-III secretion system. Proteins chaperoned in the cytosol of S. flexneri are 
secreted into the epithelial cells´ cytoplasm through a pore formed by IpaB and IpaC. IpaC polymerises 
actin, IpgD dissociates the plasma membrane from the actin cytoskeleton, VirA destabilises 
microtubules and IpaA forms a complex with vinculin, depolymerising actin. This creates cell surface 
extensions which form around the bacterium, driving the epithelial cell to take up S. flexneri into a 
vacuole.  
6. IpaB and IpaC lyse the vacuole, releasing S. flexneri into the epithelial cell´s cytoplasm. The S. flexneri 
protein, IcsA is displayed on only one pole of the bacterium, creating a polymerised actin tail behind the 
bacterium. This propels S. flexneri through the cytoplasm until it contacts the plasma membrane, the 
force of the contact creates a protrusion into the neighbouring epithelial cell. Both membranes are lysed 
by IpaB and IpaC, releasing S . flexneri into the neighbouring epithelial cell.  
7. Intracellular S. flexneri induces the epithelial cell to release IL-8. IL-8 and the IL-1b released from 
apopotic macrophages are chemotactic to PMN cells (represented by dotted arrows), attracting and 
inducing them to migrate through the epithelial layer to the lumen. This epithelial disruption amplifies 
S. flexneri invasion of the epithelial layer. 
 
S. flexneri invades epithelial cells through a macropinocytic process, where S. flexneri-
induced rearrangements of the host cell cytoskeleton engulf the bacterium into a vacuole 
(Fig. 1). The virulence plasmid pWR100 of S. flexneri encodes two loci crucial to this 
invasive phenotype, the ipa locus and the mxi-spa locus (Fig. 2).  
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Figure 2: The virulence plasmid pWR10023 
The virulence plasmid pWR100 is composed of 213 494 bp. Sequence analysis identified 93 DNA fragments 
that have over 90 % identity with known insertion sequence (IS) elements. 
 
The ipa operon encodes the ‘‘invasion plasmid antigens’’, IpaA, IpaB, IpaC and IpaD, which 
are the effectors of bacterial entry into the host cell. The mxi-spa operon encodes the 
components of a type-III secretion system, which is a flagella-like structure used to deliver 
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proteins, such as the Ipa proteins, from the bacterial cytoplasm to the cytoplasmic membrane 
or even cytosol of the host cell24. The mxi-spa operon and IpaB, IpaC and IpaD are essential 
for in vitro epithelial cell invasion25,26. The Ipa proteins are synthesized and stored within the 
bacteria, where they are associated with chaperone proteins until secretion is activated by 
contact with a host cell17,27. A complex formed by IpaB and IpaD may play a role in the 
regulation of this secretion28. Both proteins are hydrophobic allowing this complex to insert 
into the membrane of the host cell to form a pore29. It is presumed that the other effector 
molecules, delivered by the type-III secreton, are able to access the host cytoplasm through 
this pore. The C-terminal domain of IpaC activates host cell Rho GTPases, triggering actin 
polymerisation and filopodial extensions in the vicinity of the bacteria30. IpaA is secreted into 
the cytosol of the host epithelial cell where it binds the cytoskeleton-associated protein 
vinculin. The IpaA–vinculin complex depolymerises actin filaments, organising an entry foci 
around the bacterium30,31. IpgD is injected into the epithelial cell by the S. flexneri type-III 
secretion system, where it acts as a phosphoinositide phosphatase, uncoupling the plasma 
membrane from the actin cytoskeleton, allowing membrane extensions to form22. 
The macropinocytic vacuole containing the Shigella bacterium is rapidly lysed by the IpaB 
invasin, which acts as membranolytic toxin in the phagosome membrane, releasing Shigella 
into the host cell cytoplasm32. S. flexneri can replicate inside the cytoplasm of epithelial cells 
in vitro with a doubling time of 40 minutes. Epithelial cells are observed undergoing necrotic-
like death during shigellosis (Fig. 1)33. Shigella is able to exploit the host cells actin assembly 
machinery to move through the host cell cytoplasm and into adjacent epithelial cells. This 
intra- and intercellular spread is a crucial step in the virulence of Shigella and is driven by the 
outer membrane protein, IcsA (VirG)34-36. Actin polymerisation at the pole of the bacterium 
creates propulsive force, which drives the bacterium through the cytoplasm of the cell until it 
contacts the host cell membrane, forming a protrusion into the neighbouring epithelial cell37. 
The bacteria are then surrounded by two cellular membranes, which are lysed by secreted 
IpaB and IpaC38. Thus, Shigella is able to replicate and spread within the intestinal epithelial 
layer whilst avoiding exposure to the extracellular environment and its circulating immune 
cells19. 
 
II.3. Caspase-1 (ICE) 
Importantly, phagocytic cells such as macrophages or dendritic cells are the primary target of 
intracellular pathogens such as Shigella. Within the macrophage, Shigella can survive using 
distinct virulence mechanisms and can induce apoptosis of the infected macrophages through 
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activation of caspase-1 mediated by IpaB17,18. Caspases form a family of aspartate-specific 
cysteine endopeptidases. Further investigations identified a family of molecules that were 
named caspases, because they all had a cystein residue at their catalytic sites and exhibited 
protease activity targeting the aspartate residue of the substrate protein39. To date, 14 
mammalian caspases have been identified, of which 11 have human homologs40. Many of the 
caspase family members are activated during programmed cell death and their proteolytic 
activity is a central biochemical feature of the apoptotic process41. Extensive studies of 
caspases in inflammation and apoptosis validated the enzymes as attractive drug targets42. 
Caspase-1 (also known as interleukin 1β-converting enzyme or ICE) was originally identified 
as a monocyte-specific endopeptidase responsible for the post-translational processing of the 
proinflammatory cytokine interleukin 1β (IL-1β)43-45, a major mediator of inflammatory 
diseases such as rheumatoid arthritis. Soon thereafter, caspase-1 was shown to process 
interleukin-18 (IL-18), a cytokine structurally similar to IL-1 that is involved in T-cell 
activation46. Caspase-1 is expressed as a procaspase-1 zymogen that is processed into a 
catalytically competent form through autoproteolysis induced by protein oligomerization in 
vitro47, but may require caspase-5 for efficient activation in vivo (Fig. 3)48-50.  
 
 
Figure 3: Primary structure of human IL-1β-converting enzyme precursor51 
Full-length p45 ICE may be cleaved at four Asp-X cleavage sites indicated to produce mature heterodimeric 
p10/p20 ICE. 
 
The cleavage reaction removes the 119-residue propeptide and an 18-residue sequence that 
separates the large (p20; residues 120–298) and small (p10; residues 317–404) subunits of the 
mature enzyme (Fig. 3). The functional form of caspase-1 is thought to be a tetramer 
composed of two p20–p10 heterodimers52,53. Caspase-1 is expressed in cells of the 
monocytic/macrophage cell line and in pancreatic cancer cells54. 
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II.3.1. Activation of caspase-1 
Activation of inflammatory caspases, such as caspase-1 and caspase-5, occurs upon assembly 
of an intracellular complex, designated the inflammasome (Fig. 4). 
 
 
 
Figure 4: The Inflammasomes55 
Unknown exogenous (from bacteria) or endogenous (bacteria, viruses: “danger signals”) ligands bind to the 
LRRs of NALPs and induce assembly of the complex. FIIND, F-interacting domain. 
 
Inflammasome is a name given to a large, signal-induced multiprotein complex, a so-called 
caspase-activating platform, that mediates the activation of pro-inflammatory caspases. 
Platform proteins generally consist of a ligand sensing domain (frequently repeats of domains, 
the structure of leucine-rich repeats, LLR), a nucleotide binding oligomerization domain 
(NACHT), and a recruitment domain (CARD, PYD). 
In the Ipaf inflammasome Ipaf associates with caspase-1 and activates caspase-1 upon 
overexpression (Fig. 3)56-58. In the NALP1 inflammasome NALP1 recruits the adaptor protein 
ASC. The CARD region of ASC then interacts with and activates caspase-1. In addition, 
NALP1 binds and activates caspase-5. In the NALP1 inflammasome complex, caspase-5 and 
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caspase-1 are therefore brought into close proximity thereby facilitating crossactivation. Thus, 
in contrast to the NALP1 inflammasome, the NALP3 inflammasome activates only caspase-
155. 
II.4. Caspase-1 and S. flexneri 
II.4.1. Apoptosis of macrophages 
Once released into the intraepithelial pocket of the M cell, Shigella is engulfed by resident 
macrophages, possibly through a bacterial driven macropinocytic event similar to Shigella 
entry of epithelial cells59. S. flexneri is able to evade the killing mechanisms of the 
macrophage by IpaB mediated lysis of the phagocytic vacuole (Fig. 1). The membrane lysing 
properties of the virulence plasmid IpaB invasin allows the bacteria to gain free access to the 
cytoplasm32. Once in the macrophage cytosol, secreted IpaB binds and activates caspase-160. 
Procaspase-1 undergoes autocatalytic cleavage into p10 and p20 fragments, which form the 
active caspase-1 tetramer. Activation of p45 ICE occurs through a sequential series of 
proteolytic steps to generate p35, p22/p12, and p20/p10 fragments of progressively increasing 
catalytic activity61. 
IpaB, a 62-kDa protein, is necessary and sufficient to induce programmed cell death in 
macrophages60. The binding of IpaB to caspase-1 is crucial in the induction of apoptosis in 
macrophages infected with virulent S. flexneri60. 
Caspase-1 dependent apoptosis is not an immunologically silent cell death, as activated 
caspase-1 cleaves and activates the pro-inflammatory cytokines IL-1b and IL-1846. 
Macrophage apoptosis occurs within 4 h of in vivo Shigella infection, releasing bacteria into 
the sub-mucosa62. 
 
II.5. Tumor-associated macrophages (TAMs) 
Solid tumors comprise not only malignant cells, but also many other non-malignant cell types. 
The tumor microenvironment contains many resident cell types, such as adipocytes and 
fibroblasts, but it is also populated by migratory haematopoietic cells, most notably 
macrophages, neutrophils and mast cells. These haematopoietic cells have pivotal roles in the 
progression and metastasis of tumors63-67, and this work will focus on one such class - the 
tumor-associated macrophages (TAMs). Pollard argues (2004) that tumor microenvironment, 
in a similar way to that seen in normal development, educates macrophages to perform 
supportive roles that promote tumor progression and metastasis (Fig. 5)68. 
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Figure 5: Macrophages have important developmental roles68 
The immunological and repair functions of macrophages are well documented. It is known that they are among 
the first cells to arrive at sites of wounding and/or infection, where they perform several functions. They produce 
cytokines and chemokines to orchestrate the recruitment and actions of other immune cells, and produce growth 
factors, angiogenic factors and proteases to promote tissue repair. They also kill pathogens through the 
production of reactive oxygen and nitrogen radicals and present foreign antigens to cytotoxic T cells. Less well 
appreciated is their important role in tissue morphogenesis during development. Developmental defects include 
osteopetrosis, dermal hypoplasia, aberrant development of the sex-steroidhormone feedback response in the 
brain, delayed and aberrant pancreatic morphogenesis and impaired branching morphogenesis of the mammary 
gland. In the case of mammary gland69, as shown in the figure, the ends of the developing ducts form a unique 
multi-laminate structure called the terminal end bud (TEB). As these TEBs form, they recruit macrophages; the 
absence of these in the Csf-1-null mutant mouse results in delayed ductal development and a poorly branched, 
atrophic ductal tree. This shows that cells of the mononuclear phagocytic lineage have important developmental 
roles through their remodelling and trophic functions. It seems likely that tumors co-opt the normal 
developmental roles of macrophages to promote their own development and invasion through the surrounding 
stroma65. In contrast to normal epithelia, however, tumor cells - owing to intrinsic transforming mutations - have 
lost positional identity, and so they continue to send out ‘help me’ signals that result in invasion into the 
vasculature.  
 
TAMs are recruited to tumors by a range of growth factors and chemokines, which are often 
produced by the tumor cells themselves (Fig. 6)66,67,70. Clinical studies have shown a 
correlation between an abundance of TAMs and poor prognosis70. These data are particularly 
strong for breast, prostate, ovarian and cervical cancers. In contrast to colorectal cancer, 
where high TAMs numbers tended to be found in patients with a good prognosis or those with 
less recurrence, increased TAM density is usually associated with advanced tumor 
progression and metastasis71.  
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II.5.1. TAMs and Cytokines 
The local cytokine milieu in the tumor tends to block the immunological functions of these 
newly recruited mononuclear phagocytes - such as antigen presentation and cytotoxicity - 
towards tumors, and diverts them towards specialized TAMs that are immunosuppressed 
(Fig. 6)72. A principal component of this cytokine mixture is CSF-1, which locally blocks the 
maturation of dendritic cells so that they are unable to present antigens and promotes the 
development of immunosuppressed trophic TAMs. The cytokine profile of the tumor 
microenvironment is therefore important to the phenotype of the local mononuclear 
phagocytes. In determining this balance, another macrophage colony-stimulating factor GM-
CSF together with interferon-γ (IFN- γ), are likely to be important, as these direct 
macrophages towards more cytotoxic and antigen-presenting phenotypes73. 
  
II.5.2. TAMs and tumor progression 
The clinical evidence described above indicates that an abundance of TAMs has a negative 
impact on patient survival in many tumor types (Fig. 6)68. 
 
 
Figure 6: Pro- and anti-tumorigenic properties of macrophages depend on the cytokine 
microenvironment in the tumor68 
Tumors are populated by macrophages and dendritic cells that are derived from mononuclear phagocytic 
progenitor cells. In many tumors, a high concentration of soluble colony-stimulating factor-1 (CSF-1) educates 
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macrophages to be trophic to tumors and, together with interleukin-6 (IL-6), inhibits the maturation of dendritic 
cells. This creates a microenvironment that potentiates progression to metastatic tumors. By contrast, CSF-1 
presented in a transmembrane form on the tumor surface activates macrophages to kill tumor cells. This - 
together with high concentrations of IL-4, IL-12, IL-13 and GM-CSF - causes dendritic cells to mature, allowing 
the presentation of tumor antigens to cytotoxic T cells, with the consequent rejection of the tumor. 
 
Lin et al. used mice carrying a null mutation in the gene that encodes Csf-1 (colony 
stimulating factor-1) to prevent macrophages accumulating in mammary tumors of transgenic 
mice74. In this macrophage-deficient mice, the incidence and initial rates of growth of primary 
tumors were not different from those seen in normal mice, but the rate of tumor progression 
was slowed and their metastatic ability was almost completely abrogated when compared with 
mice that contained normal numbers of macrophages. Interestingly, overexpression of Csf-1 
in wild-type mice also accelerated tumor progression and increased their metastatic rate. 
Taken together, these experiments support a role for TAMs in tumor progression and 
metastasis and provide experimental support for the clinical observations that increased TAM 
density promotes tumor malignancy. 
 
II.5.3. Functions of TAMs 
Macrophages are therefore multifunctional cells, the phenotypes of which are modified by the 
local environment, and have important roles in the morphogenesis of tissues. The diverse 
functions of TAMs are summarized in figure 7. 
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Figure 7: Pro-tumorigenic functions of tumor-associated macrophages68 
Macrophages are recruited to tumors by chemotactic factors and provide many trophic functions that promote 
tumor progression and metastasis. These tumor-associated macrophages (TAMs) migrate to hypoxic areas within 
the tumor, where they stimulate angiogenesis by expressing factors such as vascular endothelial growth factor 
(VEGF), angiopoietins (ANG1 and ANG2), and recruit other haematopoietic cells such as mast cells and 
neutrophils. TAMs also promote tumor invasion by producing proteases - such as urokinase-type plasminogen 
activator (uPA), matrix metalloproteinase 9 (MMP-9) and cathepsins - that break down the basement membrane 
and remodel the stromal matrix. MMP-9 also contributes to angiogenesis. Various growth factors and 
chemokines such as epidermal growth factor (EGF), transforming growth factor-β (TGF-β), interleukin-8 (IL-8) 
and tumor necrosis factor-α (TNF-α) contribute to the migration of tumor cells towards vessels and provide 
proliferative and anti-apoptotic signals to these cells. Macrophages that are attracted to sites of inflammation or 
tissue breakdown can also initiate or promote tumorigenesis through their synthesis of oestrogens and the 
generation of mutagens as a by-product of their production of reactive oxygen and nitrogen-oxide radicals. 
 
It is widely recognized that tumors require angiogenesis to grow beyond a certain size. This 
process involves a wide range of soluble mediators that are both stimulatory and inhibitory, 
including basic fibroblast growth factor (bFGF), VEGF, the angiopoietins (ANG1 and 
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ANG2), IL-1, IL-8, tumor necrosis factor-α (TNF-α), thymidine phosphorylase (TP; also 
known as vascular-derived endothelial growth factor), the matrix metalloproteinases MMP-9 
and MMP-2, and nitric oxide (NO)11,75. These molecules, which are expressed in a 
coordinated spatial and temporal fashion, result in the proliferation and migration of 
endothelial cells, matrix remodelling and the eventual formation of stabilized vessels76. 
Macrophages are perfectly designed to promote these processes, as their monocytic precursors 
can migrate into sites where they differentiate into macrophages, and these wandering cells 
can synthesize the required angiogenic molecules on demand in specific locations77. 
Macrophages are important, although not the only producers of VEGF, which is a key 
component of the process of angiogenesis in tumors78,79. It was suggested that hypoxia - or the 
cytokines that are produced in response to this condition - is one of the local attractants for 
macrophages, and that hypoxia itself upregulates the transcription factor hypoxia-inducible 
factor-2α (HIF-2α) in macrophages. HIF-2α, in turn, induces VEGF expression (Fig. 7)66,79. 
TAMs also produce many other proangiogenic cytokines for example. they are key producers 
of TNF-α80. 
In conclusion, migratory TAMs are equipped to enter areas of the tumor where 
vascularization is needed. Here, these cells synthesize angiogenic regulators, which results in 
the formation of new vessels that allows further tumor growth and access of tumor cells to the 
vasculature for escape into the circulation. At these sites, a complex mixture of factors - 
ranging from hypoxia to cytokines - controls the expression of these regulators. This is 
consistent with the hypothesis that macrophages are educated to perform specialized tasks at 
specific sites. 
 
II.5.4. TAMs and therapeutic opportunities 
The presence of TAMs in a tumor provides an environment that enhances the survival, 
proliferation and migration of epithelial cells that have accumulated primary oncogenic 
mutations. However, macrophages might have an even more sinister role by playing a 
significant part in establishing the primary oncogenic events in epithelial cells (Fig. 7). There 
is a growing body of evidence to indicate that inflammation - as a result of chronic infection, 
continuous exposure to irritants or genetic makeup - is a causative event in many cancers. 
Pollard argued (2004) that microenvironment educates macrophages to take on specific 
phenotypes that can increase the risk of cancer and, once cancers are formed, promote their 
progression68. The intracellular regulators of these different tumor promoting pathways might 
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therefore be potential therapeutic targets. The experiments in mouse models that are described 
above - in which tumor progression and metastasis are reduced by the ablation of CSF-1- 
support this idea. Another antitumor strategy is for example the immunization against 
molecules overexpressed by TAMs and thereby remodel the tumor microenvironment that 
attracts these macrophages and mediates their function81. So TAMs represent a promising 
target to therapeutic intervention and for this reason our experimental approach is to target 
and to deplet this tumor promoting TAMs with attenuated bacteria like Shigella and 
Salmonella. 
 
II.6. Attenuated bacteria 
In our project the wildtype Shigella flexneri M90T can not be used, because it is highly 
virulent and disease causing. Therefore we wanted to engineer an attenuated Shigella strain 
which is negatively affected on its growth ability in comparison to the wildtype strain Shigella 
flexneri M90T. In this context “attenuated” means weakened or thinned. Attenuated strains of 
disease-causing bacteria and viruses are often used as vaccines. The weakened strains are 
used as vaccines because they stimulate a protective immune response while causing no 
disease or only mild disease in the person receiving the vaccine. 
 To establish a metabolic block we planed to knockout a gene of an important amino acid 
pathway such as the gene aroA. In this way the engineered metabolic mutant is expected to 
show a reduction in growth rate. On the other hand this constructed mutant should not be 
affected in its virulence in comparison to the Shigella wildtype strain because the mutant 
should still be able to invade eukaryotic cells, to induce apoptosis in macrophages by 
activating caspase-1 and to spread to neighbouring cells. In contrast to the strain described in 
this work dedicated for bacterial tumor therapy, attenuated vaccine strains against shigellosis 
usually bear attenuations in both growth and virulence. An example is the live attenuated 
SC602 vaccine using S. flexneri 2a which was developed at the Pasteur Institute. In this 
vaccine, deletions were made in iucA (gene of an iron transport island) as well as virG/icsA 
genes82. 
 And also other studies have shown that an aroA-knockout in other bacteria such as 
Salmonella leads to an attenuation in bacteria83. 
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II.6.1. The enzyme 5-Enolpyruvylshikimate-3-phosphate synthetase (AroA) 
5-Enolpyruvylshikimate-3-phosphate (EPSP) synthase (AroA) is a key enzyme in the 
aromatic amino acid biosynthetic pathway in microorganisms and plants (Fig. 8). 
 
 
Figure 8: The aromatic amino acid biosynthetic pathway 
 
Higher animals, with the exception of some protozoa, lack the aromatic biosynthesis path and 
must take up all needed aromatic metabolites from the nutrition. 
Blocking the path for aromatic biosynthesis in bacteria such as Shigella therefore causes 
requirement for at least the three major aromatic amino acids and for p-aminobenzoate 
(pABA), needed for making folic acid, which Shigella cannot assimilate from their 
environment84. Folats are cofactors needed for several enzymatic reactions involving the 
transfer of 1-carbon fragments, used in the biosynthesis of purines, thymine, serine and 
panthothenate and also of formyl-Met-t-RNA needed for the initiation of new polypeptide 
chains. 
The necessity for tyrosine, phenylalanine or tryptophan would not be expected to prevent the 
growth of Shigella strain in the tissues of an animal host since these amino acids (acquired 
from the diet or by recycling cellular protein) are available in plasma. By contrast, there is no 
mechanism ensuring the presence of pABA in cytosol or plasma despite its rapid conjugation 
and excretion, which explains the reduced virulence of for example pABA-requiring 
Salmonella typhi mutant85. Sansonetti and colleagues showed that a complete block in 
aromatic biosynthesis by an aroA-knockout led to an attenuated Shigella strain, and so this 
strain is worth to trail as a vector for live attenuated bacterial tumor therapy34,86. 
 
II.7. Transgenic mouse models 
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To investigate the complex tumor/stroma relationships and the role of TAMs in tumor growth 
we decided to use transgenic mice besides the 4T1-induced breast cancer model. Syngenic 
murine tumor models like the 4T1-cell induced breast cancer model involve rapidly growing 
tumors which are sometimes highly immunogenic87. These tumors are often anaplastic and 
therefore not a good model for the slow-growing well-differentiated human tumors. In 
addition, rapidly growing models may not develop the complex tumor/stroma relationships 
which are targeted by many novel therapies87. Transplantable tumors have often been derived 
from cell lines selected for high viability in vitro, and thus may be more resistant to apoptosis 
than their in vivo counterparts87. Consequently there is a need for a spontaneous and 
metastatic tumor model in immunocompetent mice. The major advantage of this model is a 
closer resemblance to the biological mechanisms of the human disease87. Non- or weakly-
immunogenic tumors arise in this immunocompetent mice spontaneously and stochastically. 
This provides a better parallel for the development of human malignancies and makes it more 
likely that metastases will arise via the same mechanisms as in human cancer. This is of 
potential value in preclinical studies of therapy, adjuvant or maintenance, and 
chemoprophylaxis. Recent data suggested that these tumors are biologically diverse like 
human tumors, in between one individual mouse as in between littermates or different mouse 
strains87. 
For this reasons we also used transgenic mouse models like the spontaneous breast cancer 
MMTV-HER2/neu VFB model and the transgenic lung cancer S-PC-c-Raf-BxB-11 model to 
investigate the role of TAMs in tumor growth87.  
 
II.7.1. MMTV-HER2/neu FVB mice 
To investigate the role of TAMs in breast tumor growth and progression we also used the 
transgenic breast cancer model MMTV-HER2/new FVB besides the artificial 4T1-induced 
breast tumor model. 
 
The HER2 (ErbB-2 and c-neu) receptor 
The HER2/new gene is a proto-oncogene, which is overexpressed in approximately 25-35 % 
of breast cancers. It is a member of the ErbB protein family, more commonly known as the 
epidermal growth factor receptor (EGF-R) family. HER2/new has also been designated as 
CD340 (cluster of differentiation 340). It is a cell membrane surface-bound receptor tyrosine 
kinase and is normally involved in the signal transduction pathways leading to cell growth 
and differentiation. HER2/new plays a crucial role in the pathogenesis of breast cancer which 
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is exploited by approved breast cancer treatments (Herceptin®). The oncogene her2 is so-
named because it has similar structure to human epidermal growth factor receptor, or HER1.  
In our studies we used transgenic mice that express the HER2/new gene under the control of 
the mouse mammary tumor virus (MMTV) promoter (Fig. 9)88.  
 
 
Figure 9: Structure of the MMTVIc-neu transgene88 
The unshaded region represents sequences within the pBR322 vector backbone. The transcriptional start site 
within the MMTV LTR is illustrated by the lower arrow and the 5' noncoding sequences derived from the 
MMTVIv-Ha-ras vector pA9 are illustrated by the shaded box. The boundaries of the her2 (c-neu) cDNA and 
SV40 processing signals are shown by the appropriate arrows. Relevant restriction endonuclease sites are also 
identified in the figure88. 
 
Transgenic mice generated to evaluate the relevance of a cellular proto-oncogene like her2 (c-
neu) to mammary development and tumorigenesis utilized the mouse mammary tumor virus 
long terminal repeat (MMTVLTR) sequence to target the expression of HER2/new to the 
mammary epithelium of virgin, pregnant and lactating mice88-90. These mice express the 
HER2/new transgene in the mammary gland at very high levels and develop HER2-positive 
mammary tumors within 6–8 months88.  
 
II.7.2. SP-C-c-Raf-BxB-11 mice 
In order to investigate the role of TAMs in lung adenomas and to find out whether TAMs 
isolated from lung tumors can be infected and depleted by attenuated Shigella, we used 
transgenic SP-C-c-Raf-BxB-11 mice which express a oncogenic c-Raf. 
 
II.7.2.1. C-Raf: keyplayer in Ras/Raf signaling 
The Ras/Raf/MEK/ERK signaling pathway is an evolutionary conserved signaling cascade 
that links receptor activation at the cell membrane to the modification of cytoplasmic or 
nuclear targets that are required for the execution of developmental programs as well as for 
cell survival and proliferation91. As summarized in figure 10 a wide variety of growth factors 
and differentiation factors, as well as tumor-promoting substances, employ this pathway. 
Most of these stimuli activate Ras proteins by inducing the exchange of GDP with GTP, 
which converts Ras into its active conformation92. 
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Figure 10: The mitogenic cascade93 
The mitogenic cascade as well as the Akt signaling pathway is initiated by growth factors binding to the 
receptor. The signal is carried on by a cascade of protein kinases leading to transcriptional activation of proteins 
possessing anti-apoptitic and cell cycle stimulating properties. Ras: receptor activated substrate, Raf: Rous 
sarcoma associated factor, Mek: mitogen-activated protein kinase or Erk kinase, Erk: extra cellular signal 
regulated kinase, TF: transcription factor, PI: phosphatidylinositol, PI3K: phosphatidylinositol-3 kinase, Akt: 
protein kinase B/Akt, c-Myc: v-Myc myelocytomatosis viral oncogene homolog. 
 
Activated Ras functions  as an adapter that  binds to Raf kinases with high affinity and causes 
their translocation to the cell  membrane, where Raf activation takes place94. Once activated, 
Raf kinases transmit the signal to downsteam MEK1, 2 kinases, which in turn phosphorylate 
and activate ERK1, 2 kinases. Afterwards phosphorylated ERK activates a multitude of 
cytoplasmic and nuclear transcription factors that are important for cell fate decisions and 
cell-type-specific functions91,93. 
 
II.7.2.2. The serine / threonine kinase c-Raf-1 
Mammals possess three Raf proteins: a-Raf, b-Raf and c-Raf-1. All three Raf isoforms share 
Ras as a common upstream activator and MEK as the only commonly accepted downstream 
substrate95,96. The ubiquitously expressed c-Raf is certainly the best studied. Knocking out the 
c-raf-1 gene in an inbred background results in death during midgestation. In an outbred 
strain, c-Raf-1 knock-out mice die shortly after birth, showing general growth retardation and 
developmental defects that are most apparent in placenta, lung and skin. Overall, the 
phenotype of the knock-out mice are reasonably consistent with the expression data, and 
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indicate that c-Raf-1 serves a general role in tissue formation92. Overexpression of c-Raf-1 
induces adenomas in murine lung97. 
Inactive c-Raf-1 is localized in a multi-protein complex of 300-500 kDa98. Ras can interact 
with two domains in the c-Raf-1 N-terminus: the Ras-binding domain (RBD; amino acids 55-
131) and the cysteine-rich domain (CRD; amino acids 139-184)99,100. Cell culture experiments 
have shown that deletion of the NH2-terminal regulatory domain leads to a constitutively 
active kinase that is highly oncogenic in animals as well as in cultured cells101,102. 
Kerkhoff and colleagues have generated transgenic mice [(C57BL/63DBA-2)F1] expressing 
the wild-type human c-Raf-1 protein or the oncogenically activated NH2-terminal deletion 
mutant c-Raf-1-BxB under the control of human SP-C promoter (Fig. 11). c-Raf-1-BxB is a 
constitutively active c-Raf-1 kinase and is highly transforming in cell culture 
experiments103,104. In mice, the SP-C gene is expressed in type II epithelial cells lining the 
lung alveoli105-107. The promoter region of the human SP-C gene has been shown to direct the 
expression of chimeric genes in transgenic animals in a lung epithelial cell-specific manner106 
 
 
Figure 11: Structure of the c-Raf-1 and c-Raf-1-BxB proteins108  
Structure of the c-Raf-1 and c-Raf-1-BxB proteins and recombinant DNA constructs directing the expression of 
the raf sequences under the control of the SP-C promoter. For the generation of transgenic mice, expression 
cassettes of the SP-C-c-raf-1 or SP-C-c-raf-1-BxB vectors were released by digestion with the NdeI and NotI 
restriction endonucleases. The purified DNA fragments were injected into fertilized eggs of C75BL/63DBA-2 
F1 mice. The c-Raf-1-BxB protein lacks the regulatory NH2-terminal sequences of the c-Raf-1 protein, including 
the Ras interaction domain. In contrast to the wild-type c-Raf-1 kinase, which requires activating upstream 
regulators, the c-Raf-1-BxB kinase is constitutively active. In mice, the SP-C gene is expressed in type II 
epithelial cells lining the lung alveoli105-107. 
 
The group around Kerkhoff showed that lung-targeted overexpression of c-Raf-1 protein in 
transgenic mice leads to the development of lung adenomas within 1 year of age108. 
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In this work we were specifically interested in the role of TAMs in c-Raf-1 induced lung 
cancer biology and therefore examined whether a depletion of TAMs in this transgenic mouse 
model could ba achieved by an infection with Shigella. 
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II.8. Goal of the project 
 
The goal of this project is to analyse the distribution of attenuated Salmonella and Shigella 
after i.v. application in tumors with high numbers of macrophages. For this reason we wanted 
quantitatively determine the bacterial counts of bacteria in the extracellular space or within 
tumor cells, distinguishing between the macrophage and non-macrophage fraction. We 
wanted to show that TAMs are the primary target of bacteria like Salmonella and Shigella in a 
4T1-induced and a transgenic MMTV-HER2/new breast cancer model. We also wanted to 
investigate whether metabolically attenuated, virulent Shigella strains, but not avirulent 
Shigella strains or Salmonella, are able to activate caspase-1 and induce apoptosis in TAMs at 
all time points in both breast cancer models. In addition we wanted to find out whether this 
unrestricted apoptosis induction causes a substantial depletion of TAMs, which could be 
correlated with a therapeutic effect. Finally, we wanted to investigate if apoptosis induction 
by Shigella could be confirmed ex vivo in freshly isolated TAMs from mouse lung adenomas 
and a human ovarian carcinoma. 
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III. Material 
 
III.1. Instruments 
Instrument Manufacturer 
Bacterial incubator Heraeus B 6200 
Bacterial shaker Scientific innova 4330 New Brunswick 
Bacterial shredder Fast Prep FP120 Thermo Electron Corporation 
Cell culture incubator Heraeus Instrument 
Cell culture microscope Leica 
Cell counter chamber Bürker 
Clean bench Heraeus 
Developing cassette Dr. Goos-suprema GmbH 
Developing machine Agfa 
DNA Sequencer ABI PRISM 373 ABI 
Electrophoresis power supply Bio-Rad 
Electrophoresis unit small Bio-Rad 
Freezer (-20°C) Liebherr 
Freezer (-80°C) Nunc Advantage 
Fridge (4°C) Liebherr 
Gene pulser Bio-Rad 
Horizontal electrophoresis gel PEQLAB 
Heat block Liebisch 
Ice machine Scotsman 
Mega centrifuge J-6B Beckman; Megafuge 1.0 R Heraeus 
Microwave Siemens 
Mini centrifuge 5417R, Biofuge 15 Eppendorf; Heraeus 
Mini-Protean II Fine scale Bio-Rad 
Pipettes Eppendorf 
Thermocycler T-Gradient Thermoblock Biometra 
Timer Roth 
Vortex genie Scientific industries 
FACS machine Becton Dickinson 
pH-meter Microprocessor, WTW 
MACS® permanent magnet  Miltenyi Biotec GmbH 
MACS® mini columns Miltenyi Biotec GmbH 
 
III.2. Chemical reagents  
Reagent Manufacturer 
1 kb DNA ladder Invitrogen, MBI 
Adenosin-5’Triphosphate (ATP) Sigma 
Agarose, ultra pure Invitrogen 
Ammonium Acetate Sigma 
Ammonium peroxydisulfate (APS) Sigma 
Avertin Sigma 
Bacto-Agar Roth 
Bovine serum albumin (BSA) Sigma 
Bromphenolblue Sigma 
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Reagent Manufacturer 
β-Mercaptoethanol Roth 
Caspase-1 inhibitor YVAD-CHO (2,5 
mM) 
Bio Cat 
Congo red dye (Cr) Sigma 
Diaminobenzidin (DAB) Sigma 
dNTPs MBI 
Entellan Merck 
Eosin Sigma 
Ethylenediaminetetraacetic acid-disodium 
salt (EDTA) 
Fermentas 
Ethanol Roth 
Ethidiumbromide Invitrogen 
Gentamicin Sigma 
Giemsa dye Sigma 
Glycerol Sigma 
Hematoxylin Sigma 
Hoechst 33342 dye Sigma 
Isopropanol Merck 
Kanamicin Sigma 
L-arabinose Sigma 
Mowiol Calbiochem 
Ponceau Sigma 
Protein ladder, BenchMark TM Invitrogen, MBI 
SeaPlaque Agarose  Biozym Scientific GmbH 
SDS ultra pure Roth 
Staurosporine (4 µM) Sigma 
TEMED Roth 
Triton X-100 Sigma 
Trypanblue Sigma 
Trypticase soy agar (1.2 % agar) (TSA) Difco Laboratories 
Xylol Roth 
 
III.3. Buffers and Solution 
Name  Composition (Concentration) Manufacturer 
Acrylamide/Bis solution 40 % Acrylamide/N,N’-metylene-bis-
acrylamide, 37.5:1 (2.6 % C), pre made 
solution 
Bio-Rad 
Ampicillin stock 100 mg/ml Ampicillin in water Sigma 
Carbonate buffer 7 g/l sodium hydrogen carbonate Applichem 
Carbonate buffer pH 9.6 4.2 g/l sodium hydrogen carbonate  
 5.3 g/l di-sodium hydrogen carbonate Sigma 
Chloramphenicol stock 20 mg/ml Chloramphenicol in ethanol Sigma 
Coomassie Protein pre made solution Thermo Scientific 
Erythrocyte-Lysisbuffer 100 ml 50 mM Tris, pH 7.65  
 
900 ml 155 mM ammonium chloride, 
pH 7.2 Applichem 
G418 (geniticin) 50 mg/ml G418 sulphate in water Sigma 
Gentamicin 50 mg/ml Gentamycin in water, pre Sigma 
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Name  Composition (Concentration) Manufacturer 
made 
Kanamycin stock 25 mg/ml Kanamycin in water Sigma 
Laemmli buffer  Sigma, ,  
 Applichem 
 
50 mM Tris-HCl pH 6.8, 10 % glycerol,  
5 % β-mercaptoethanole, 2 % sodium 
dodecyl sulphate (SDS), 0.05 % 
bromphenol blue Roth 
6 x DNA-loading buffer 
 
1 mg/ml bromophenol blue, 2 mg/ml 
xylene cyanol FF, 400 mg/ml sucrose 
Sigma              
Sigma 
Phosphate buffered saline (PBS) ready made, 9.55 g/l Applichem 
PBS milk PBS, 5 % nonfat dried milk powder Applichem 
PBS TWEEN PBS, 0.05 % TWEEN Roth 
SDS PAGE buffer 3 g/l Tris, 14.4 g/l, 1 g/l SDS Applichem 
Stripping Buffer Applichem 
 
1 M glycine, 1 % SDS; Adjust pH to 2.5 
with HCl  Applichem 
TBE buffer ready made, 20 ml/l Applichem 
Towbin buffer 3 g/l Tris, 14.4 g/l, 20 % methanol Applichem 
 
III.4. Enzymes 
Items Manufacturer 
BioTherm Taq DNA polymerase Genecraft 
Pfu polymerase Stratagene 
DNAse Fermentas 
Dispase Invitrogen 
 
III.5. Consumable Material 
Name Manufacturer 
96-well plates Nunclon A/S, Greiner bio-one 
Cell culture flasks; 75 cm3 and 125 cm3  Greiner bio-one 
Cell culture plates; 24 wells  Greiner bio-one 
Gene pulser cuvette, 0.1 cm electrode gap  Bio-Rad 
Cryo.s tubes 1.5 ml  Greiner bio-one 
Insulin syringe  Braun 
Micro tube; 1.5 ml, 2 ml  Sarstedt 
Nitrocellulose; Hybond ECL Amersham 
Parafilm  Hartenstein 
Pasteurpipettes  Hartenstein 
Petri dish, 12 cm  Greiner bio-one 
Pipette ipps  Hartenstein 
Sterile filter Millex-GS; 0.22 μm Millipore 
X-ray film Amersham 
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III.6. Molecular weight standards 
 
Figure 12: Molecular weight standards 
a) Molecular weight standards for DNA: Gene Ruler TM 1 kb-DNA-Ladder (Fermentas) (left) and New 
England BioLabs 50 bp-DNA-Ladder (right). b) Molecular weight standards for proteine: BenchMark™ Pre-
Stained Protein Ladder (Invitrogen) 
 
III.7. Cell culture media 
Items Manufacturer 
RPMI 1640 with L-Glutamin Gibco 
Minimal Essential Medium Invitrogen 
Trypsin/EDTA Gibco 
L-Glutamin, 200 mM (100x) Gibco 
MEM non-essential amino acids, 100x Invitrogen 
MEM Natriumpyruvat, 100 mM Invitrogen 
Natriumbicarbonat 7,5 % Invitrogen 
Dulbecco`s Mod Eagle Medium (DMEM) 
with high glucose 
Gibco 
Dulbecco`s PBS Gibco 
Fetal calf serum (FCS) Pan Biotech GmbH 
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III.8. Chemicals 
All Chemicals not mentioned elsewhere were obtained from Sigma, Difco, Roth or 
Applichem. 
 
III.9. Antibodies used for Western Blot analysis, Cell separation 
(MACS®), FACS analysis and Histology 
Antibodies for Western Blot analysis Manufacturer 
Anti-caspase-1 (ICE, rabbit polyclonal) Sigma 
Anti-cleaved PARP (cPARP, mouse polyclonal) BD Pharmingen 
Anti-GAPDH (mouse polyclonal) Chemicon international 
Anti-β-actin (rabbit polyclonal) Sigma 
Anti-rabbit IgG conjugated peroxidase GE heltcare 
Anti-mouse IgG conjugated peroxidase GE heltcare 
 
Antibodies for MACS® Technology Manufacturer 
Anti-mouse F4/80 (rat monoclonal, clone BM8) Acris Antibodies GmbH 
Anti-human F4/80 (rat monoclonal, clone BM8) Santa Cruz 
Anti-rat IgG antibody, labelled with magnetic beads Miltenyi Biotec GmbH 
 
Antibodies for FACS Conjugated Manufacturer 
Anti-mouse CD11b  Fluorescein isothiocynate (FITC) Miltenyi Biotec GmbH 
Anti-mouse Gr-1 Phycoerythrin (PE) Miltenyi Biotec GmbH 
Anti-mouse F4/80 Phycoerythrin (PE) Acris Antibodies 
→ As isotype controls we used a mouse IgG2B Isotype (R & D Systems) conjugated with   
     either phycoerythrin (Clone 133303) or fluorescein (Clone 133303) 
 
Antibodies for fluorescence microscopy Conjugated Manufacturer 
Anti- mouse monoclonal Cytokeratin (clone 
AE1+AE3) 
 Abcam 
Anti-mouse IgG Tetramethyl 
Rhodamine Iso-
Thiocyanate (TRITC) 
Dianova 
 
Antibodies for Histology Conjugated Manufacturer 
Anti- mouse F4/80 (rat monoclonal, clone 
BM8) 
 Acris Antibodies 
GmbH 
Anti- mouse CD45 (rat monoclonal, clone 
30-F11) 
 BD Pharmingen 
Anti- cow Cytokeratin (rabbit polyclonal)  DAKO 
Anti-rat IgG Peroxidase Vector Laboratories 
Anti-goat IgG  Biotin DAKO 
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III.10. Kits 
Items Manufacturer 
ECLTM Western blotting detection reagents Amersham 
QIAEX® II Gel Extraction Kit Qiagen 
QIAGEN® Plasmid Kit (Mini, Midi, Mega) Qiagen 
QIAquick® PCR purification Kit Qiagen 
RNeasy® Mini Kit Qiagen 
First Strand® cDNA Synthesis Kit Fermentas 
Peroxidase-based detection kit Vector Laboratories 
 
III.11. Software 
Program Manufacturer 
CellQuest Pro 4 BD 
GraphPad Prism 4 GraphPad Software, Inc 
MS Excel 2003 Microsoft 
MS Word 2003 Microsoft 
Photoshop CS2 Adobe 
Improvision Openlab 3.1.7. Apple 
 
III.12. Bacterial strains 
Bacteria strain Relevant characteristics References 
Salmonella 
enterica 
serovar. 
Typhimurium 
aroA SL7207 
pTolCKan 
hisG46, DEL407 [aroA544::Tn10 (Tc. S. )]84 Stocker, BAD, 
200084 
Shigella flexneri 
M90T serotype 
5a 
[streptomycin (Sm) resistant]109,110 Maurelli, AT, 
1984110; Allaoui, A, 
1992109  
Shigella flexneri 
M90TΔaroA 
serotype 5a 
[streptomycin (Sm) resistant]109,110, AroA-deletion This work  
Shigella flexneri 
BS176 serotype 
5a 
noninvasive variant of M90T, lacking the virulence 
plasmid pWR10023,111 
Sansonetti, PJ, 
1982111; Buchrieser, 
C, 200023;  
Shigella flexneri 
BS176ΔaroA 
serotype 5a 
noninvasive variant of M90T, lacking the virulence 
plasmid pWR10023,111, AroA-deletion 
This work  
DSM 21058 Shigella flexneri M90TΔaroA serotype 5a, Patented 
strain (Patent 08-01Z) deposited at German 
Collection of Microorganisms and Cell Cultures, 
[streptomycin (Sm) resistant]109,110, AroA-deletion 
 
This work  
     →Trypticase soy agar (1.2 % agar) (TSA) containing 100 mg of Congo red dye (Cr) per   
      litre was used to select Cr+ clones of Shigella spp.110  
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III.13. Cell lines 
Cell line (culture medium) Source 
B78-D14 
(1640 RPMI +2 mM L-glutamin + 10 % (v/v) FCS + 10 µl/ml 
Hygromycin B + 8 µl/ml G418) 
Rymsa, B112; Lode H N113 
4T1 
(1640 RPMI + 2 mM L-glutamin + 10 % (v/v) FCS) 
ATCC: CRL-2539 
P815-PSA 
(RPMI 1640, 10 % fetal bovine serum + 1x MEM non-essential 
amino acids + 1 mM sodium pyruvate + 2 mM L-glutamine + 
50 mM β-mercaptoethanol + 10 µl/ml Hygromycin B + 8 µl/ml 
G418) 
Fensterle, J114 
HeLa ATCC CCL-2 
RAW 264.7 
(RPMI 1640, 10 % fetal bovine serum + 1x MEM non-essential 
amino acids + 1 mM sodium pyruvate + 2 mM L-glutamine + 
50 mM β-mercaptoethanol) 
ATCC TIB-71 
J774A.1 
(1640 RPMI + 2 mM L-glutamin + 10 % (v/v) FCS) 
ATCC TIB-67 
 
III.14. Mouse lines 
Mouse line Source 
BALB/cOIaHsd Harlan Winkelmann GmbH 
C57BL/6JOIaHsd Harlan Winkelmann GmbH 
DBA/2 Harlan Winkelmann GmbH 
MMTV-HER2/new FVB  The Jackson Laboratory88 
SP-C-c-RAF-BXB-11 MSZ (Würzburg)108 
→ All procedures involving mice were conducted in accordance with the Regierung von 
Unterfranken (Würzburg, Germany). All animals were housed at the Institut für 
Medizinische Strahlenkunde und Zellforschung (MSZ) animal care facility. 
 
III.15. Liquid medium and agar plates for E. coli, S. typhimurium 
and S. flexneri cultures 
Items compounds 
LB medium 10 g bacto trypton 
5 g yeast extract 
10 g NaCl 
Ö The pH of the medium was adjusted to 7.0 with 10 M NaOH. The total volume was 
added up to 1000 ml with dH2O and autoclaved at 121 °C, 15 psi for 20 min 
 
 
BHI medium 37 g BHI 
Ö Powder was dissolved in 1000 ml dH2O and autoclaved at 121 °C, 15 psi for 20 min 
 
LB Agar Plates 10 g bacto trypton 
5 g yeast extract 
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Items compounds 
10 g NaCl 
15 g agar 
Ö Components were dissolved in 1000 ml dH2O and autoclaved at 121 °C, 15 psi for 20 
min. After  autoclaving, the medium was cooled down to 60 °C to add respective 
antibiotic, immediately distributed in bacteria dishes under the laminar hood and 
allowed to solidify at RT. The plates were stored at 4 °C. 
 
BHI Agar Plates 37 g BHI 
15 g agar 
Ö Components were dissolved in 1000 ml dH2O and autoclaved at 121 °C, 15 psi for 20 
min. After  autoclaving, the medium was cooled down to 60 °C to add respective 
antibiotic, immediately  distributed in bacteria dishes under the laminar hood and 
allowed to solidify at RT. The plates were stored at 4 °C. 
 
III.16. Plasmids 
Name Relevant characteristics References 
pTolCKan KanR, copie of TolC Hotz, C, unpublished 
pKD3  CmR, π dependent, chloramphenicol resistance 
gene, flanked by FLP recombinase recognition 
sites (FRT sites)115 
Datsenko, KA, 2000115 
(Andersen, C; Würzburg) 
pKD4 KanR, π dependent, kanamycin resistance gene, 
flanked by FLP recombinase recognition sites 
(FRT sites)115 
Datsenko, KA, 2000115 
(Andersen, C; Würzburg) 
pCP20 Ampicillin and CmR plasmid that shows 
temperature-sensitive replication and thermal 
induction of FLP synthesis116 
Cherepanov, PP, 1995116 
(Andersen, C; Würzburg) 
 
III.17. Primers 
Name Sequence (5`→ 3`) (Source: MWG) 
AroA_up GGGGTTTTTATTTCTGTTGTAGAGAGTTGAGTTCATGGAATCGTGTAGGCTGGA
GCTGCTTC 
AroA_down GGCCGTGCATTTGGGATCAAGAATCGTCACTGGTGTATCTGCATATGAATATCC
TCCTTA 
AroAFr_up GATTTCTACCGCAATGACG 
AroAFr_down GGAAACAAGTGAGCGTTTC 
C1 TTATACGCAAGGCGACAAGG115 
C2 GATCTTCCGTCACAGGTAGG115 
K1 CAGTCATAGCCGAATAGCCT115 
K2 CGGTGCCCTGAATGAACTGC115 
Casp1RT_left TGCCCTCATTATCTGCAAC 
Casp1RT_right GGTCCCACATATTCCCTCCT 
actin s1 GTCGTACCACAGGCATTGTGATGG 
actin as GCAATGCCTGGGTACATGGTGG 
pWR100_up GATGCAGGCCAAGAGGTTAG 
pWR100_down GCGTTGATGACCGCATC 
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IV. Methods 
 
IV.1. General cloning techniques 
 
IV.1.1. Plasmid DNA isolation 
Mini preparation of plasmid DNA: A single colony from the bacterial plate was inoculated in 
5 ml LB or BHI medium supplemented with selective antibiotic and cultured overnight at 
37 °C, 190 rpm/min in a shaking incubator. Mini preparation of plasmid DNA was done 
according to the instructions of Qiagen (Plasmid mini kit). Plasmid DNA was dissolved in 
dH2O and stored at –20 °C. 
 
Midi preparation of plasmid DNA: A single colony from the bacterial plate was inoculated 
into 50 ml of LB or BHI supplemented with antibiotic and cultured overnight at 37 °C, 190 
rpm/min in a shaking incubator. Plasmid DNA was isolated using Qiagen kit (Plasmid midi 
kit). Plasmid DNA was dissolved in dH2O and stored at –20 °C. 
 
Mega preparation of plasmid DNA (endotoxin free): A single colony from the bacterial plate 
was inoculated into 500 ml of LB or BHI supplemented with antibiotic and cultured overnight 
at 37 °C, 190 rpm/min in a shaking incubator. Plasmid DNA was isolated using Qiagen kit 
(EndoFree Plasmid mega kit). Plasmid DNA was dissolved in PBS endotoxin free and stored 
at –20°C. 
 
IV.1.2. DNA quantification 
DNA samples were diluted 1:25 – 1:50 depending on estimated concentrations. DNA 
concentration was determined by measuring the absorbance at λ = 260 nm (A260) in a 
spectrophotometer using a quartz cuvette. The concentration was calculated based on the 
DNA coefficient of 1 unit at 260 nm being equal to 50 μg/ml DNA. The purity of the DNA 
was determined by analysis of the A260/A280 ratio. 
 
IV.1.3. DNA agarose gel electrophoresis 
Agarose gel electrophoresis was employed to check the progression of a restriction enzyme 
digestion, to quickly determine the yield and purity of a DNA isolation or PCR reaction and 
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to size fractionate DNA molecules, which then could be excised from the gel. An agarose gel 
was prepared according to the protocol described by Sambrook and Russel117 and after 
cooling down to 50 °C ethidium bromide (Roth) was added to a final concentration of 1 
μg/ml. DNA samples were electrophoreted in 1 x TBE buffer (180 V, 30-40 min).  
 
IV.1.4. Gel extraction 
The desired DNA fragment was quickly extracted from an agarose gel using a scalpel under 
low strength UV light (λ=300 nm) to limit DNA damage. The gel slice was then purified 
using the Qiagen Gel Extraction kit (Qiagen). The gel slice was accordingly solubilized for 10 
min, or until completely dissolved, at 50 °C in a buffer containing chaotropic salts.  
 
IV.1.5. General PCR method 
PCR is an enzymatic method for in vitro synthesis of multiple copies of specific sequences of 
DNA. The reaction mixture for general PCR containing the following components: 
 
           template-DNA                    1-5 μl   
           primer 1 (10 pmol/μl)         0,5 μl 
           primer 2 (10 pmol/μl)         0,5 μl 
           25 mM MgCl2                        2 μl 
           10 mM dNTPs                    0,5 μl 
           10 x PCR buffer                     5 μl 
            Taq polymerase                   0.5μl 
            dH2O                          up to 50 μl 
 
The PCR mixture was immediately incubated in thermocycler for amplification using cycling 
programm as follows: 
1.  95°C        3 min     denaturation 
2. 95°C         1 min      denaturation 
3. 50°C         1 min      annealing                       30 CYCLES 
4. 72°C         90 sec     elongation 
5. 72°C         3 min 
6.   4°C          break 
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The annealing temperature is dependent on primers, normally 5-10 °C below the Tm of the 
primers. The time of elongation is determined taking into account of the characteristic of the 
polymerase and the length of desired DNA fragments. Taq polymerase can synthesize 1 kb of 
DNA in 1 min, and Pfu polymerase requires 2 min to synthesize 1 kb of DNA. In this work 
Taq polymerase was used for screening. 
 
IV.1.6. Purification of PCR products 
Purification of DNA fragments like PCR products or restriction digests was carried out using 
the Qiagen PCR purification kit. The purification principal is based on the adherence of the 
DNA to a silica-gel covered membrane in a spin-column format. The washing steps removed 
nucleotides, primers and short stranded DNA molecules ensuring that only longer stranded 
DNA molecules were retained in the eluate. 
 
IV.1.7. Generation of Shigella aroA-mutant 
Gene knockout by Datsenko and Wanner115 
Linear DNA containing antibiotic resistance genes were prepared from pKD3 using the 
method described by Datsenko and Wanner115. At first a PCR-product was generated by using 
primers AroAFr_up and AroAFr_down with 36 nucleotid extensions that are homologous to 
the AroA-gene. As a template, the pKD3 plasmid, which carries a chloramphenicol resistance 
gene flanked with FRT sites, was used. The next step was the transformation of the PCR-
product in electrocompetent S. flexneri BS176 strain, which express the lambda red 
recombinase. Chloramphenicol resistant colonies were then screened with primers AroA_up 
and AroA_down. Finally, the resistance cassette was eliminated by using the helper plasmid 
pCP20 carrying the flipase gene. Subsequently, the plasmid with temperature sensitive 
replicon was eliminated by incubation at 43 °C. The resulting strain was termed S. flexneri 
BS176ΔaroA.  
To create a strain which is attenuated in growth but not in its virulence we used the 
engeneered strain S. flexneri BS176ΔaroA. Subsequently the 200 kb virulence plasmid 
pWR100 of S. flexneri M90T was isolated by the large-construct kit (QIAGEN). After that 
this virulence plasmid and the helper plasmid pCP20116, carrying an ampicilin-resistance, 
were transformed in the already constructed S. flexneri BS176ΔaroA strain. After this double 
transformation and incubation at 30 °C overnight the ampicilin-resistant colonies were 
screened for the virulence plasmid pWR100 (pWR100_up 5`-GATGCAGGCC 
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AAGAGGTTAG-3`; pWR100_down 5`-GCGTTGATGACCGCATC-3`) and for the aroA-
knockout (AroAFr_up 5`-GATTTCTACCGCAATGACG-3`; AroAFr_down 5`-
GGAAACAAGTGAGCGTTTC-3`). This strain was termed S. flexneri M90TΔaroA. The 
pCP20 plasmid containing a temperature sensitive replicon was cured by incubation overnight 
at 43 °C. 
 
IV.2. Transformation of S. typhimurium and S. flexneri 
 
IV.2.1. Preparation of competent cells 
1 ml of overnight culture was inoculated in 49 ml LB medium (1:50) in side arm flasks and 
grown at 37 °C with vigorous agitation (about 3 h) till to OD600 0.6 – 0.8. Bacterial cells were 
transferred to sterile 50 ml polyproylene tubes and centrifuged at 2,000 x g for 20 min at 4 °C. 
The pellet was first washed with 50 ml ice-cold 10 % glycerin and centrifuged at 2,000 x g for 
20 min at 4 °C. Then the pellet was washed with 25 ml ice-cold 10 % glycerin and 
centrifuged at 2,000 x g for 20 min at 4 °C.  After that the pellet was washed again with 10 ml 
ice-cold 10 % glycerin and centrifuged at 2,000 x g for 20 min at 4 °C. Finally the pellet was 
resuspended in 0.5 ml ice-cold 10 % glycerin. These competent cells were used directly for 
transformation or aliquoted and stored at –80 °C. 
 
IV.2.2. Transformation of competent cells 
Electroporation was used to transform S. typhimurium and S. flexneri. It was carried out with 
fresh or frozen competent cells prepared as described above. 1 – 5 μl of DNA (100 ng) was 
added to 50 – 70 μl of competent cells on ice. After a short incubation of 1 min on ice the mix 
was gently transferred to pre-chilled 0.1 cm electroporation cuvette and electroporated (Bio-
Rad, Gene Pulser at 1.8 kV, 25 µF and 200 Ohm, program: bacteria). After electroporation the 
cells were immediately resuspended in BHI medium and then gently transferred into a sterile 
1.5 ml tube. After 1 h of incubation at 37 °C, the cell suspension was plated on selective agar-
plates and incubated at 37 °C overnight. 
 
IV.3. Preparation of bacteria infection aliquots 
For the production of bacteria aliquots for an in vivo infection of mice the Salmonella strains 
from the respective glycerolstocks were freshly plated out on LB agar-plates with appropriate 
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antibiotics. The next day an overnight culture was generated from a single colony. The strains 
have to be cultivated up to an optical density (OD600) of 1.0-1.5. Subsequently, the work must 
be continued on ice, so that a further growth is prevented. The bacteria cells were pelleted 
with 2,000 x g and 4 °C for 20 min and washed twice with 20–40 ml of steril ice-cold PBS. 
After the second wash step the pellet was resuspended in 10 ml ice-cold PBS with 20 % final 
concentration glycerol, aliquoted to 1 ml portions and frozen at –80 °C. Two days before the 
infection two aliquots were thawed in each case in order to determine the bacteria’s number 
per ml. The bacteria’s number is calculated thereby as follows: 
Bacteria’s number / ml (CFU) = number of colonies × number of dilutions of 10 times × 10 
For in vitro infections of eukaryotic cells Salmonella grown to stationary phase were used, if 
not indicated otherwise. Bacteria were washed three times in ice cold PBS (2,000 x g, 10 min, 
4 °C) and then bacteria`s number / ml (CFU) were determined. 
Shigella strains were freshly plated on LB agar plates with appropriate antibiotics from the 
respective glycerolstocks for infection. The next day an overnight culture was manufactured 
from a single colony. The strains were cultivated up to an optical density (OD600) of 0.8-1.0. 
OD600 of 1 means approximately 1 x 108 bacteria. Bacteria were washed three times in ice 
cold PBS (2,000 x g, 10 min, 4 °C) and then bacteria`s number / ml (CFU) was determined as 
described previously. 
 
IV.4. Gene expression analysis 
 
IV.4.1. RT-PCR 
Up to 1 x 107 cells of every cell line (B78-D14, 4T1 and J774A.1), were disrupted in RLT 
buffer and homogenized by the protocol of Rneasy® Mini Kit (Qiagen) for RNA isolation. 
The cDNA synthesis was performed by the protocol of First Strand® cDNA Synthesis Kit 
(Fermentas). DNA concetration was determined as described before. Subsequently PCR was 
peformed with Taq Polymerase. To determine caspase-1 expression the primers Casp1RT_left 
5`-TGCCCTCATTATCTGCAAC-3` and Casp1RT_right 5`-GGTCCCACATATTCCCTC 
CT-3` were used. The ß-actin-gene was used as a control (Primer: actin s1: 5`-
GTCGTACCACAGGCATTGTGATGG-3` and actin as 5`-GCAATGCCTGGGTACAT 
GGTGG-3`). 
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IV.4.2. SDS-PAGE separation and Western Blot analysis of proteins 
Shigella-infected or uninfected cells from six-well cell culture dishes were washed twice with 
PBS and lysed in 120 µl of 2 x Laemmli buffer. Insoluble material was removed by 
centrifugation (20,000 g , 5 min, 4 °C). The supernatants were removed and the cell pellets 
were resuspended in Laemmli buffer with β-mercaptoethanol. 
For immunoblotting, 10 – 30 µl of lysates were separated. SDS-PAGE of the extracted 
proteins was performed essentially as described by Laemmli118, but using the apparatus and 
methods from Bio-Rad. Briefly, a 1.0 mm or 0.75 mm thick discontinuous gel was cast using 
a 10 % running gel overlayed with a 4 % stacking gel. The gel was loaded with appropriate 
protein suspensions and a weight marker for comparison  and run for 1-2 h at 0.04 mA.  
Whole proteins were separated by SDS-PAGE118 and analysed by immunoblotting. The 
separated proteins were transferred to nitrocellulose filter according to the method of 
Towbin119. After the blotting the nitrocellulose membrane was treated for 2 h with 5 % 
mager-milk (Applichem) in order to block all the idrophobic sites. Subsequently, the proteins 
were probed with anti-caspase-1, anti-PARP, anti-β-actin or anti-GAPDH antibody and were 
incubated overnight at 4 °C. Then the membrane was washed with PBS-Tween (washing 
buffer) three times for 10 min. The bound antibodies were detected respectively by addition of 
anti-rabbit and anti-mouse horseradish peroxidase conjugated immunoglobulins. These were 
incubated 2 h at room temperature. After this time the membrane was washed with PBS-
Tween three times for 30 min, then the bound antibodies were followed by ECL detection kit. 
 
Components of a Laemmli gel: 
20 ml running gel   
 5 % 6 % 7,5 % 10 % 12 % 12,5 % 
10 ml 
stacking gel 
Acrylamid/ 
Bisacr. 40 % 
2,7 
ml 
3,2 
ml 
3,8 
ml 
5 
ml 
6,2 
ml 
6,5 
ml 1,1 ml 
dH20 
14,4 
ml 
13,9 
ml 
13,3 
ml 
12,1 
ml 
10,9 
ml 
10,6 
ml 7,55 ml 
3M Tris  
pH 9,0 2,5 ml 
1M Tris pH 6,8 
1,25 ml 
20 % SDS 100 µl 50 µl 
TEMED 20 µl 10 µl 
10 %  APS 200 µl 100 µl 
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IV.4.3. Stripping of the nitrocellulose membrane 
Stripping is the term used to describe the removal of primary and secondary antibodies from a 
nitrocellulose membrane membrane. Stripping is useful when one wants to investigate more 
than one protein on the same blot, for instance a protein of interest and a loading control like 
GAPDH or β-actin. Stripping of the nitrocellulose membrane was performed by incubating in 
stripping buffer for 15 min two times. Subsequently there is a short incubation time in tap 
water and 5 min in PBS/Tween. After that the nitrocellulose membrane is ready for blocking 
stage described previously.  
 
IV.5. In vitro experiments 
 
IV.5.1. Fluorescence microscopy of cells 
4T1 cells and RAW 264.7 macrophages were grown on coverslips for 36 h in 10 % fetal calf 
serum plus RPMI medium 1640. After two washings with icecold PBS, cells were fixed for 
15 min with 3.7 % paraformaldehyde at room temperature. After 5 min quenching with 10 
mM NH4Cl in PBS, the primary antibody (Mouse monoclonal to pan Cytokeratin, prediluted) 
was incubated for 30 min with cells. After three washes with PBS, Tetramethyl Rhodamine 
Iso-Thiocyanate (TRITC)-labeled secondary antibody (dilution 1:200) were diluted in 
PBS/BSA and incubated with cells for 30 min. After three washes with PBS, the cells were 
treated with 0.1 µg/ml Hoechst 33342 dye for 30 min. Excess dye was washed out with PBS 
and water. The cells were covered with Mowiol and subjected to fluorescence microscopy. 
 
IV.5.2. HeLa cell invasion- and survival assay 
Invasion and survival in HeLa cells was assessed using a modified gentamicin protection 
assay as previously described120. HeLa cells grown to semiconfluence were trypsinized and 
adjusted to 2 x 105 cells/ml. Six-well plates were seeded with 2 ml of HeLa cell suspension 
and incubated overnight to reach 90 % confluence. HeLa cells were washed, and medium was 
changed 2 h before the addition of bacteria. Log-phase (OD600: 0.6 – 0.8) cultures of Shigella 
(grown in LB medium) were added at an estimated MOI of 100 and plates were incubated at 
37 °C for 1 h. Subsequently plates were washed three times with PBS and then incubated with 
DMEM containing gentamicin (100 µg/ml) for 1 h at 37 °C in 5 % CO2. HeLa cells were 
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lysed in a 0.1 % Triton X-100 solution for 10 min at different time points and CFU was 
determined by plating serial dilutions on agar plates and by counting the colonies.  
 
IV.5.3. Intra- and intercellular growth assay 
IV.5.3.1. Giemsa staining 
To study bacterial intracellular multiplication and behavior of cell-to-cell spreading 
histologically, Giemsa staining of the cells was performed. Briefly, HeLa-cells (1 x 105) in 45 
mm diameter tissue culture plates on coverslips (Ø 20 mm) infected at a multiplicity of 
infection of 100 for 1 h, were washed two times with PBS and fixed for 5-7 min with 
methanol at room temperature. Plates were air dried and stained for 20 min with Giemsa dye 
(1:20). Afterwards the plates were washed three times with distilled water, they were air dried 
and observed under oil immersion. Time points of 1 h and 4 h p.i. were examined.  
 
IV.5.3.2. L-Top agar assay (Cell to cell spreading assay) 
To determine cell to cell spread with a growth attenuated strain a new assay was employed. 
HeLa cells (7 x 105 per well) in grown in 6-well tissue culture plates were infected at a MOI 
of 500 for 1 h and then washed twice with PBS. Infected cells were irradiated at 20 Gy. 
Subsequently, a monolayer of uninfected HeLa cells grown in 6 well plates were incubated 
with the irradiated Shigella-infected HeLa cells in a ratio of 70 : 1 for 2 h, 8 h and 12 h. After 
1 h incubation with 100 µg/ml gentamicin, the concentration of gentamicin was reduced to 10 
µg/ml. At all time points the number of infected cells was determined by plating serial 
dilutions on agar plates and by counting the colonies.  
 
IV.5.4. Assay for apoptosis induction 
IV.5.4.1. In vitro activation of caspase-1 
1 x 106  RAW 264.7 macrophages per well were seeded and incubated overnight at 37 °C and 
5 % CO2. The next day the macrophages were infected at a MOI of 10 with S. flexneri M90T, 
S. flexneri M90TΔaroA (both mid-logarithmic growth phase) and S. typhimurium ΔaroA 
(stationary growth phase) for different time points (1 h, 2 h and 3 h p.i.). Subsequently, a 
Western Blot analysis for caspase-1 activation of the cell lysate was performed. 
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IV.5.4.2. In vitro activation of caspase-1 and induction of apotosis by aroA-mutants 
To determine the capacity of the S. flexneri ΔaroA-mutants to induce caspase-1 activation and 
apoptosis, 1 x 106 J774A.1 mouse macrophages per well were seeded and incubated overnight 
at 37 °C at 5 % CO2. Next day macrophages were infected at a MOI of 100 of S. flexneri 
M90T, S. flexneri M90TΔaroA and S. flexneri BS176ΔaroA (all mid-logarithmic growth 
phase). After 1 h of infection, cells were incubated for 1 h with 300 µg/ml gentamicin. Then 
the concentration of gentamicin was reduced to 10 µg/ml for 1 h. After that the cellular 
lysates were analyzed by Western Blot analysis at different time points using an anti-caspase-
1 antibody recognizing the active 20 kDa fragment of caspase-1 and an anti-PARP antibody 
recognizing the cleaved 85 kDa fragment described as cPARP. Cleaved PARP is an approved 
marker for apoptosis121. The caspase-1 specific inhibitor YVAD-CHO was used as control. β-
actin was used as loading control. 
 
IV.5.4.3. Hoechst 33342 staining 
To investigate induction of apoptosis histologically we stained with Hochst dye. Hoechst 
33342 is a cell-permeant nuclear counterstain that emits blue fluorescence when bound to 
dsDNA. This dye is often used to distinguish condensed pycnotic nuclei in apoptotic cells. 
Hoechst dyes preferentially bind to AT regions of the DNA. These probes are UV excited 
(346 nm maximum) and emit maximally at around 460 nm (violet/blue). Hoechst 33342 has 
the advantage of being cell membrane permeant and can, therefore, stain nuclei in living cells 
as well as fixed cells. 
J774A.1 macrophages were infected with the different Shigella strains for 1 h at a MOI of 
100. After that cells were washed three times with PBS and incubated for 1 h with 100 µg/ml 
gentamicin. Subsequently macrophages were incubated for 1 h with 50 µg/ml gentamicin. As 
positiv control for apoptosis induction we used macrophages incubated with 4 µmol/l 
staurosporine for 6 h. Not infected J774A.1 macrophages were used as negativ control. After 
that, cells were fixed for 10 min in 4 % para-formaldehyde at room temperature. Then we 
washed three times with PBS. Subsequently macrophages were stained with Hoechst 33342 
dye and incubated for 10 – 15 min at room temperature or 37 °C. After that we rinsed three 
times with PBS. Subsequently stained cells were mounted in antifade mounting medium 
(Mowiol). Mounted cells were stored overnight in the dark at 4 °C. 
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IV.5.5. Gentamicin assays 
The gentamicin (an aminoglycoside antibiotic) survival assay is the most frequently used 
method for measuring eukaryotic host cell penetration by bacteria. The specificity of the assay 
for the enumeration of intracellular bacteria depends on the antibiotic’s limited penetration of 
the eukaryotic cell122,123. Thus, bacteria that have penetrated eukaryotic cells are protected 
from the bactericidal effects of gentamicin, whereas extracellular bacteria are immediately 
killed by the antibiotic. For this reason, gentamicin is routinely added to experimental media 
and events that occur subsequent to bacterial invasion, such as cell survival and replication, 
are measured. 
In order to find the optimal gentamicin concentration to determine the bacterial counts in the 
extracellular space or within tumor cells in vivo, distinguishing between macrophage and non-
macrophage fraction, we setup three gentamicin assays. 
 
IV.5.5.1. Extracellular activity of gentamicin 
In the first gentamicin assay 1 x 106 S. typhimurium ΔaroA were treated for ½ h, 1 h and 2 h 
with 50, 100, 200 and 300 µg/ml gentamicin at 37 °C. Subsequently CFU was determined by 
plating of serial dilutions on agar plates to determine the bactericidal effect of gentamicin on 
extracellular S. typhimurium ΔaroA.  
 
IV.5.5.2. Intracellular activity of gentamicin 
In the second gentamicin assay J774A.1 macrophages were infected with 1 x 106 S. 
typhimurium ΔaroA (from stationary growth phase). Bacteria were washed three times with 
DMEM medium for 10 min at 2,000 x g and 4 °C. After 1 h of infection, cells were incubated 
for 1 h with 50, 100, 200 and 300 µg/ml gentamicin at 37 °C followed by a 1 h incubation 
with 10 µg/ml gentamicin after washing with PBS. CFU was determined after cell lysis by 
plating of serial dilution on agar plates. 
 
IV.5.5.3. Gentamicin activity assay at different temperatures 
In this assay 1 x 106 S. typhimurium ΔaroA were incubated overnight at 4, 25 and 37 °C to 
investigate the gentamicin effect on S. typhimurium ΔaroA at different temperatures. Next day 
CFU was determined by plating serial dillutions on agar plates. 
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IV.6. In vivo experiments 
 
IV.6.1. Tumor cell transplantation 
Six- to eight-week-old female mice were injected subcutaneously with either 1 x 104 murine 
4T1 mammary cancer cells (ATCC: CRL-2539), 1 x 106 B78-D14112 melanoma cells or 1 x 
106 P815-PSA124 mastocytoma cells each resuspended in 100 µl PBS into each flank of 
shaven abdominal skin of BALB/c, C57Bl/6 or DBA/2 mice. 
 
IV.6.2. Monitoring of 4T1 breast tumor growth 
Balb/c mice were transplanted with 1 x 104 4T1 breast tumor cells subcutaneously and the 
tumor volume was monitored every day after by a caliper. After washing in ice-cold PBS for 
three times, cells were counted using a Bürker counting chamber. 1 x 104 cells in 100 µl of the 
suspension were injected with a 0,4×20 mm (27 G) injection syringe into each flank of shaven 
abdominal skin of Balb/c mice. 
. 
IV.6.3. I.v. infection of tumor-bearing mice with Salmonella and Shigella 
Freshly cultured Shigella were harvested at mid-logarithmic phase or infection aliquots from 
stationary phase for Salmonella were washed in PBS three times and diluted with PBS prior 
to i.v. injection. 1 x 106 bacteria in 100 µl of the suspension (determined by CFU) were 
injected with a 0,4×20 mm (27 G) injection syringe into the lateral tail vein of fixed 4T1 
induced tumor-bearing Balb/c mice 14 days post cell implantation, or into 6 month old tumor-
bearing female MMTV-HER2 mice.  
The infected animals were daily observed and if an animal should get sick and suffer, then it 
was sacrificed immediately and painless.  
 
IV.6.4. Isolation of splenocytes 
To isolate and analyze splenocytes, mice were anesthetized under CO2 atmosphere and killed 
via cervical dislocation. The abdomen was opened with scissor and forceps to ensure not to 
damage the main blood vessels. The spleen was isolated and put in PBS/BSA on ice. Then it 
was transfered in a 100 μm nylon cell strainer and pressed with a 5 ml syringe. The cell 
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strainer was washed with cold PBS/BSA until all the cells have been washed out. The effluent 
was collected. PBS/BSA was added up to 50 ml and centrifuged at 300 x g, 5 min and 4 °C. 
The supernatant was discarded and washing was repeated two times with 50 ml cold 
PBS/BSA. At the end cells were counted with a Bürker cell chamber. 
 
IV.6.5. Tumor cell isolation and staining procedures for magnetic cell 
separation (MACS®) 
 
Figure 13: Experimental schedule of cell separation 
 
Mice were sacrificed and tumors were removed, weighed and digested in 0.001 % DNase and 
2 µg/ml dispase solution for 30 min at 37 °C. After that they were homogenized with 70 µm 
and 40 µm cell strainers. Cell numbers of every cell fraction were counted using a Bürker 
counting chamber. For separation of cellular populations (Fig. 13), parts of the cells were 
labelled with the pan-macrophage anti-F4/80 (dilution 1:10) antibody for 20 min at 4 °C. 
Subsequently labelled cells were stained with an anti-IgG antibody conjugated to magnetic 
beads (10 µl antibody per 107 cells) for 10 min at 4 °C. Cell separation was performed with 
the MACS® Kit according to the manufacturers protocol (Fig. 14). Subsequently every cell 
fraction was counted using a Bürker cell chamber. 
Finally CFU and caspase-1 processing was assessed. For CFU counts, normalization was 
performed after plating (CFU/cell number, infected cells/cell number). For Western Blot 
analysis, equivalent cell numbers were loaded. 
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Figure 14: MACS® Technology 
a) Magnetic labeling of total tumor cells 
b) Magnetic cell separation 
c) Elution of the labeled cell fraction (macrophages)  
 
 
IV.6.6. Fluorescence activated cell sorting (FACS analysis) 
Flow cytometry is an analytical tool that allows cells within a heterogeneous population to be 
discriminated based on their size and different structural features including cell surface 
molecules. Cell surface antigens can be labeled with specific antibodies coupled to a 
fluorochrome. The cell suspension containing the labeled cells is directed into a thin stream 
enabling them to pass single-file through a laser beam. Each cell scatters some of the laser 
light and also emits fluorescent light at a particular wavelength excited by the laser. This is 
detected by a photocell and subsequently analyzed. 
Single cell suspension was prepared from spleen and tumor tissue as already described. 
1 x 106 cells in 50 μl PBS/BSA (FACS buffer) were labeled with anti-mouse Fc receptors 
(FcR, CD16/CD32) block antibodies (final dilution 1:50) in order to reduce FcγII/III receptor-
mediated non-specific antibodies binding which could contribute to background staining. The 
number of macrophages was analyzed following labeling of spleenocytes and tumor cells with 
a phycoerythrin (PE)-conjugated rat anti-mouse Gr-1 antibody (1:10 in FACS buffer), 
fluorescein isothiocyanate (FITC)–conjugated rat anti-mouse CD11b (1:10 in FACS buffer) 
and phycoerythrin (PE)-conjugated rat anti-mouse F4/80 (1:100 in FACS buffer). Except for 
the anti-F4/80 antibody which needed an incubation time of 30 min the others were incubated 
10 min. The incubations were performed at 4 °C and protected from the light. As isotype 
controls a mouse IgG2B Isotype conjugated with either phycoerythrin or fluorescein was used. 
Subsequently there is an incubation for 30 min on ice and in the dark. The cells were 
centrifuged 5 min, 300 x g at 4 °C and the pellets were resuspended in 100 μl FACS buffer. 
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The amount of macrophages in tumors was detected measuring a minimum of 1 x 105 cells. 
Flow cytometric analysis was performed on a FACSCalibur (BD Immunocytometry Systems) 
according to the manufacturer instructions. 
 
IV.6.7. H & E staining 
Mice with transplanted tumors of approximately 1,5 cm in diameter were sacrified and tumors 
were aseptically excised. The tumors were fixed in 4 % buffered paraformaldehyde for 24 h at 
room temperature, paraffin embedded, sectioned, and stained with hematoxylin and eosin. 
The staining method involves application of the basic dye hematoxylin, which colors 
basophilic structures with blue-purple hue, and alcohol-based acidic eosin Y, which colors 
eosinophilic structures bright pink. The basophilic structures are usually the ones containing 
nucleic acids, such as the ribosomes and the chromatin-rich cell nucleus, and the 
cytoplasmatic regions rich in RNA. The eosinophilic structures are generally composed of 
intracellular or extracellular protein. The staining protocol is as followed: 
 
Step Reagent Time 
1 xylol 10 min 
2 xylol 10 min 
3 absolute alcohol I 2-5 min 
4 absolute alcohol II 2-5 min 
5 absolute alcohol III 2-5 min 
6 70 % alcohol 5-10 min 
7 dH2O 5 min 
 
 
 
Deparaffinisation 
 
8 hematoxylin 0,30-2 min 
9 tap Water 5-10 min 
10 dH2O 2-5 min 
11 eosin 0,30–1 min 
12 dH2O 2-5 min 
13 70 % alcohol 3 min 
14 absolute alcohol I 3 min 
15 absolute alcohol II 5 min 
16 absolute alcohol III 5 min 
17 xylol 10 min 
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Step Reagent Time 
18 xylol 10 min 
At the end slides are mounted in Entellan. 
 
IV.6.8. Immunohistochemical analysis of tumors 
To identify macrophages at the tumor site, tissues were fixed in 4 % buffered 
paraformaldehyde for one day, paraffin embedded, and processed for sectioning. 
Subsequently sections were immunostained using the pan-macrophage anti-F4/80 antibody 
and specific reactivity was detected using a peroxidase-based detection kit as described 
(Vector Laboratories)69. The grade of infiltration of lymphocytes was examined by using an 
anti-CD45 antibody  and the peroxidase-based detection kit (Vector Laboratories)69. For the 
identification of epithelial cells an anti-cytokeratin antibody and a biotinylated anti-IgG 
antibody was used. At the end sections were counter-stained with hematoxylin. 
 
IV.6.8.1. Anti-F4/80 staining of TAMs 
The F4/80 antigen is a 160 kDa glycoprotein expressed by most murine macrophages.  
Expression of F4/80 is heterogeneous and is reported to vary during macrophage maturation 
and activation. The F4/80 antigen is expressed on a wide range of mature tissue macrophages 
including Kupffer cells, Langerhans, microglia, macrophages located in the gut lamina 
propria, peritoneal cavity, lung, thymus, bone marrow stroma, macrophages in the red pulp of 
the spleen and it is overexpressed on TAMs81. The ligands and biological functions of the 
F4/80 antigen have not yet been determined but recent studies suggest a role for F4/80 in the 
generation of efferent CD8+ regulatory T cells125. 
 
Step Reagent Time 
1 xylol 10 min 
2 xylol 10 min 
3 absolute alcohol I 2-5 min 
4 absolute alcohol II 2-5 min 
5 absolute alcohol III 2-5 min 
6 70 % alcohol 5-10 min 
7 dH2O 5 min 
 
 
 
Deparaffinisation 
 
 
8 Proteinase K (20 µg/ml in TE Buffer, pH 8,0),  30 min (RT) 
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Step Reagent Time 
9 1 x PBS 4 min 
10 1,5 % H2O2 in 1 x PBS 30 min 
11 1 x PBS  5 min (3x) 
12 5 % rabbit serum, 0,1 % Triton X-100 in 1 x PBS 
(Blocking) 
30 min (37 °C, 
 humidified chamber) 
13 Rat anti-mouse F4/80 (1:500) in Blocking solution 
(100 µl/slide) 
Overnight, RT 
14 1 x PBS  5 min (3x) 
15 Biotinylated rabbit anti-rat (1:200, 100 µl/slide) in 1 
x PBS 
60 min (RT, humidified 
chamber) 
16 1 x PBS (Preparation of A+B reagents before 30 
min) 
10 min (3x) 
17 ABC Complex Incubation 45 min, RT 
18 Diaminobenzidin (DAB) incubation: 1 ml DAB + 
0,8 µl 30 % H2O2 (watch-out brown color 
formation, then stop reaction with water for 5 min) 
 
19 hematoxylin 0,30-1 min 
20 tap Water 5-10 min 
21 dH2O 2-5 min 
22 70 % alcohol 3 min 
23 absolute alcohol I 3 min 
24 absolute alcohol II 5 min 
25 absolute alcohol III 5 min 
26 xylol 10 min 
27 xylol 10 min 
28 entellan  
 
IV.6.8.2. Anti-CD45 staining 
The CD45 antigen is a protein which was originally called leukocyte common antigen. The 
protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. 
PTPs are known to be signaling molecules that regulate a variety of cellular processes 
including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This gene 
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is specifically expressed in hematopoietic cells. This PTP has been shown to be an essential 
regulator of T- and B-cell antigen receptor signaling.  
 
Step Reagent Time 
1 xylol 10 min 
2 xylol 10 min 
3 absolute alcohol I 2-5 min 
4 absolute alcohol II 2-5 min 
5 absolute alcohol III 2-5 min 
6 70 % alcohol 5-10 min 
7 dH2O 5 min 
 
 
 
Deparaffinisation 
 
8 Proteinase K (20 µg/ml in TE Buffer, pH 
8,0), Cooling Down after Inkubation (25 
min, RT) 
20 min (37 °C, humidified chamber) 
9 1 x PBS 4 min 
10 2 % rabbit serum, 1 % BSA, 0,1 % Triton X-
100 and 0,05 % Tween 20 in 1 x PBS 
(Blocking) 
30 min (RT) 
11 Rat anti-mouse CD45 (1:20) in 1 x PBS 
containing 1 % BSA (100 µl/slide) 
Overnight, RT 
12 1 x PBS  10 min (3x) 
13 Biotinylated rabbit anti-rat (1:200, 100 
µl/slide) in 1 x PBS 
30 min (RT, humidified chamber) 
14 1 x PBS (Preparation of A+B reagents before 
30 min) 
10 min (3x) 
15 ABC Complex Incubation 45 min, RT 
16 Diaminobenzidin (DAB) incubation: 1 ml 
DAB + 0,8 µl 30 % H2O2 (watch-out brown 
color formation, then stop reaction with 
water for 5 min) 
 
17 hematoxylin 0.30-1 min 
18 tap Water 5-10 min 
19 dH2O 2-5 min 
20 70 % alcohol 3 min 
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Step Reagent Time 
21 absolute alcohol I 3 min 
22 absolute alcohol II 5 min 
23 absolute alcohol III 5 min 
24 xylol 10 min 
25 xylol 10 min 
26 entellan  
 
IV.6.8.3. Anti-cytokeratin staining 
Cytokeratins are intermediate filament keratins found in the intracytoplasmic cytoskeleton of 
epithelial tissue. There are two types of cytokeratins: the low weight, acidic type I 
cytokeratins and the high weight, basic or neutral type II cytokeratins. Cytokeratins are 
usually found in pairs comprising a type I cytokeratin and a type II cytokeratin. Expression of 
these cytokeratins is frequently organ or tissue specific. The subsets of cytokeratins which an 
epithelial cell expresses depends mainly on the type of epithelium, the moment in the course 
of terminal differentiation and the stage of development126. Thus this specific cytokeratin 
fingerprint allows the classification of all epithelia upon their cytokeratin expression profile. 
Furthermore this applies also to the malignant counterparts of the epithelia (carcinomas), as 
the cytokeratin profile tends to remain constant when an epithelium undergoes malignant 
transformation126. Therefore staining for cytokeratins could be used for the detection of 
residual tumor cells. 
 
Step Reagent Time 
1 xylol 10 min 
2 xylol 10 min 
3 absolute alcohol I 2-5 min 
4 absolute alcohol II 2-5 min 
5 absolute alcohol III 2-5 min 
6 70 % alcohol 5-10 min 
7 dH2O 5 min 
 
 
 
Deparaffinisation 
 
8 10 mM Citratpuffer, pH 6,0 10 min (microwave) 
9 1 x PBS 5 min (3x) 
10 3 % H2O2 in MeOH 30 min (RT) 
11 1 x PBS 5 min (3x) 
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Step Reagent Time 
12 5 % goat serum in 1 x PBS, 0,1 % 
Triton-X 100, 1 % BSA 
30 min (RT) 
13 Rabbit anti-cow Cytokeratin (1:400, 100 
µl/slide) in Blocking solution 
Overnight, 4 °C 
14 1 x PBS  10 min (3x) 
15 Biotinylated goat anti-rabbit IgG (1:200, 
100 µl/slide) in Blocking solution  
90 min, RT 
16 1 x PBS (Preparation of A+B reagents 
before 30 min) 
10 min (3x) 
17 ABC Complex Incubation 30 min, RT 
18 1 x PBS 5 min, RT 
16 Diaminobenzidin (DAB) incubation: 1 
ml DAB + 0,8 µl 30 % H2O2 (watch-out 
brown color formation, then stop reaction 
with water for 5 min) 
 
17 hematoxylin 0.30-1 min 
18 tap Water 5-10 min 
19 dH2O 2-5 min 
20 70 % alcohol 3 min 
21 absolute alcohol I 3 min 
22 absolute alcohol II 5 min 
23 absolute alcohol III 5 min 
24 xylol 10 min 
25 xylol 10 min 
26 entellan  
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IV.7. Ex vivo experiments 
 
IV.7.1. Ex vivo infection of murine cells 
Tumor cells were separated and TAMs were isolated via MACS® system like subscribed 
before. Subsequently cells were seeded in the desirable cell number in 6-well or 12-well 
plates for 3 h. Shigellae grown to logarithmic growth phase were centifuged (2,000 x g, 10 
min, 4 °C) and washed with DMEM medium three times. After 1 h of infection at a MOI 100, 
cells were incubated for 1 h with 300 µg/ml gentamicin. After that 50 µg/ml gentamicin were 
used. 2 h p.i. cells were harvested to determine CFU or were prepared for Western Blot 
analysis. 
 
IV.7.2. Ex vivo infection of murine lung cells 
Lung cells of transgenic S-PC-c-RAF-BxB-11 lung tumor mice were separated and F4/80+ 
macrophages were isolated like subscribed before. Subsequently cells were seeded in the 
desirable cell number in 6-well plates for 3 h. Shigellae grown to logarithmic growth phase 
were centifuged (2,000 x g, 10 min, 4 °C) and washed with DMEM medium three times. 
After 1 h of infection at a MOI 100, cells were incubated for 1 h with 300 µg/ml gentamicin. 
After that 50 µg/ml gentamicin were used. 2 h p.i. cells were prepared for Western Blot 
analysis. 
 
IV.7.3. Ex vivo infection of human ascites cells 
Ovarian cancer ascites were isolated from a patient and kindly provided by Dr. Jörk 
Wischhusen (Interdisciplinary Center for Clinical Research, University of Würzburg, Medical 
School, Clinics for Gynecology and Obstetrics, Würzburg, Germany) for this work. Ovarian 
cancer ascites contains both adherent cancer and non-adherent myeloid cells. Tumor cells 
were separated and TAMs were isolated with an anti-F4/80 anitbody (100 µg/ml) as described 
before. The different cell fractions isolated from an ovarian cancer patient were infected ex 
vivo with wt S. flexneri M90T, S. flexneri M90TΔaroA and S. flexneri BS176ΔaroA that had 
been grown to logarithmic growth phase, centrifuged (2,000 x g, 10 min, 4 °C) and washed 
three times with D-MEM medium. After 1 h of infection at a MOI of 100, cells were 
incubated for 1 h with 300 µg/ml gentamicin. After that, 50 µg/ml gentamicin was used. 2 h 
p.i. cells were harvested to determine CFU or were prepared for Western Blot analysis. 
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IV.8. Therapeutic approach 
 
IV.8.1. Efficacy studies 
Therapeutic efficacy of Shigella infection on tumor growth was explored in 28 six- to eight-
week-old female Balb/c mice bearing 4T1-induced tumors. Mice were injected 
subcutaneously with 1 x 104 4T1 murine breast tumor cells and tumor growth was determined 
every two days with a caliper. Tumor volume was calculated as rotation ellipsoid with the 
formula V=π/6*a*b2 with a being the maximal and b the minimal diameter of the tumor. At 
day 14 post cell implantation, mean tumor volume had reached 170 mm3 and mice were 
randomized into three groups of mice (n = 8). 1 x 106 S. flexneri S. flexneri M90TΔaroA, S. 
flexneri BS176ΔaroA or 100 µl PBS were injected into the lateral tail vein of the tumor-
bearing mice. Tumor size was monitored every second day. On day 31 post tumor cell 
implantation the naϊve and the S. flexneri BS176∆aroA group (tumor size) and two S. flexneri 
M90T∆aroA mice (macroscopic comparison of tumors, data not shown) were sacrificed. On 
day 62 post tumor cell implantation three S. flexneri M90T∆aroA mice were sacrified to 
determine CFU in tumor, liver and spleen. In addition FACS analysis was performed to 
determine the amount of macrophages in the tumor tissue. On day 66 post tumor cell 
implantation animals were re-injected with 1 x 106 S. flexneri M90T∆aroA i.v. On day 82 post 
tumor cell implantation CFU was again determined in tumor, liver and spleen tissue. In 
addition, two tumors were prepared for histological and immunohistochemical analysis. 
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IV.9. S-PC-c-RAF-BxB-11 lung tumors 
 
IV.9.1. I.v. infection of C57Bl/6 and S-PC-c-Raf-BxB-11 mice with Shigella 
S. flexneri M90TΔaroA were harvested at mid-logarithmic phase, washed three times and 
diluted with PBS prior to i.v. injection. 1 x 106 bacteria in 100 µl of the suspension were 
injected with a 0,4×20 mm (27 G) injection syringe into the lateral tail vein of fixed C57Bl/6 
or S-PC-c-RAF-BxB-11 mice.  
 
IV.9.2. Histological and immunohistochemical analysis of lung tissue 
28 days p.i. C57Bl/6 or S-PC-c-Raf-BxB-11 mice were sacrificed and lungs were fixed under 
25 cm water pressure with 4 % PBS buffered formalin. Histology was done on formalin-fixed, 
paraffin-embedded lung specimen. 6 µm-cut sections were deparaffinized, rehydrated in 
graded alcohols and haematoxylin-eosin stained.  
To identify macrophages, sections were immunostained using the pan-macrophage anti-F4/80 
antibody and specific reactivity was detected using a peroxidase-based detection kit as 
described (Vector Laboratories)69. The level of infiltration of lymphocytes was examined by 
using an anti-CD45 antibody and the peroxidase-based detection kit (Vector Laboratories)69. 
Epithelial cells were detected by an anti-Cytokeratin antibody and a biotinylated anti-IgG 
antibody. At the end sections were counter-stained with hematoxylin. Staining procedures 
were performed as described. 
 
IV.9.3. Shigella flexneri M90TΔaroA i.v. infection of Balb/c mice 
In this animal study we wanted to investigate whether the lung tissue is targeted by S. flexneri 
M90TΔaroA after an intravenous application. Therefore we injected 1 x 104 S. flexneri 
M90TΔaroA i.v. and sacrified two mice per time point (1 d, 7 d, 14 d and 28 d p.i.) to 
determine the CFU in the lung tissue. 
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V. Results 
 
V.1. Analysis for caspase-1 expression in tumor cells 
 
Intracellular bacteria like Salmonella and Shigella induce apoptosis in macrophages via 
activation of caspase-129. To determine whether caspase-1 expression is restricted to 
macrophages and not present in tumor cells, we checked caspase-1 expression in murine 
J774A.1 macrophages, the 4T1 breast tumor cell line and the transfected B16 cell line B78-
D14 melanoma cell line via RT-PCR (Fig. 15 left panel) and Western Blot analysis (Fig. 15 
right panel). 
 
 
 
Figure 15: Caspase-1 is exclusively expressed by macrophages 
Analysis of caspase-1 expression by RT-PCR (left) and Western Blot analysis (right). 
When ICE gene is expressed, there is a product of 250 bp (left). In  Western Blot analysis the anti-caspase-1 
antibody detects the caspase-1 precursor protein of 45 kDa (right). β-actin was used as loading control.` 
 
So RT-PCR and Western Blot analysis showed that the caspase-1 precursor protein is not 
expressed in the 4T1 or B78-D14 tumor cell lines (Fig. 15).  
Tumors consist of a complex mixture of transformed cells and stroma cells. In addition, 
stromal cells frequently display a distinct phenotype compared to equivalent cells in their 
physiological surrounding. In many tumors, tumor-associated macrophages represent a major 
component of the leucocytic infiltrate.  
 
 
V.2. Immunohistological examination for infiltration of 
macrophages in tumor tissue 
 
Macrophage infiltration has been described in several human tumors including breast78,127,128 
and ovarian carcinoma129. To determine the level of infiltrated TAMs in different 
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experimental tumor models we stained macrophages with an anti-F4/80 antibody in paraffin 
embedded tissues of different tumor models (Fig. 16).  
 
 
Figure 16: Substantial amounts of TAMs in different mouse tumor models 
Tumors with diameters of approximately 1,5 cm were isolated from mice injected s.c. with 1 x 106 B78-D14 
cells (a), 1 x 104 4T1 cells (b) and 1 x 106 P815-PSA cells (c). In addition, spontaneous breast tumors from 
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transgenic MMTV-HER2/new FVB were isolated (d). Tumor tissue was fixed and embedded in paraffin. Tumor 
sections were immunostained with a biotinylated anti-F4/80 monoclonal antibody and subsequently counter-
stained with hematoxylin (right panels). Staining with avidin-horseradish peroxidase without F4/80 antibody was 
performed as a control (left panels). Scale bars represent 50 µm. 
 
In all tumors examined, we detected hotspots of macrophages (Fig. 16, brown staining). 
Because TAMs are widespread in human breast carcinomas and are associated with negative 
prognosis, we used the artificial 4T1 model and the transgenic MMTV-HER2 tumor model 
for further studies70,74,130,131. 
 
V.3. Tumor targeting by Shigella flexneri M90T 
 
We performed at first an experiment to analyse if Shigella flexneri M90T is able to infiltrate, 
replicate and then preferentially accumulate in the tumor tissue. Balb/c mice were 
transplanted with 1 x 104 4T1 breast tumor cells and the tumor volume was monitored every 
second day (Fig. 17). Tumor volume was determined by following formula: 
 
2
6
baV ⋅⋅Π=  if a > b 
 
 
Figure 17: 4T1 cell-induced tumor growth 
1 x 104 4T1 murine breast tumor cells were applicated s.c. into ten Balb/c mice. Tumor volume was determed 
every other day by a caliper. 
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On day 27 (tumor volume 600-800mm3) 4 x 106  Shigella flexneri M90T were injected 
intravenously (Fig. 18).  
 
Figure 18: S. flexneri M90T accumulates in the tumor tissue 
Shigella flexneri M90T is able to infiltrate, replicate and preferentially accumulate in the tumor tissue. On day 7 
tumor tissue, liver and spleen were excised and CFUs were determined. Bars represent means +/- SD of ten 
organs analyzed. 
 
One week later there were 105-106 bacteria located in the tumor tissue and only 102-103 
bacteria were found in the liver and the spleen tissue. This enrichment is comparabel to results 
obtained previously in the same model system using Listeria and Salmonella strains3. 
 
V.4. Construction of S. flexneri aroA-mutants 
 
Because of the high virulence of the Shigella flexneri M90T wildtype strain we attempted to 
create an attenuated Shigella flexneri strain, which is still able to induce apoptosis in 
macrophages by caspase-1 activation. 
In this work the Shigella flexneri strains M90T and BS176, which is the plasmidless non-
virulent variant, were used. The knockout of the aroA-locus in the Shigella flexneri BS176 
strain was performed by using the method of Datsenko and Wanner115. 
To allow a genetically defined comparison of growth-attenuated virulent and non-virulent 
strains, we first deleted the genomic aroA-locus in the avirulent Shigella flexneri strain BS176 
using the method of Datsenko and Wanner and subsequently added the virulence plasmid 
pWR100 by electroporation.  
At first we generated a linear PCR-product by using primers AroA_up and AroA_down (=H1, 
H2; see Fig. 19: step 1) with 36 nucleotid extensions that are homologous to the AroA gene. 
As template we used the pKD3 plasmid which carries an chloramphenicol resistance gene 
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flanked FRT sites. The next step was the transformation of the PCR product in the competent 
Shigella flexneri BS176 strain, which expresses the lambda red recombinase coded by plasmid 
pKD46 (Fig. 19: step 2). This recombinase is essential for homologous recombination and its 
expression is regulated by an inducable promoter. The chloramphenicol-resistant 
transformants were then checked for aroA-gene disruption via PCR (Fig. 19: step 3). The last 
step was the elimination of the resistance cassette by using an helper plasmid, which 
expressed the FLP recombinase (Fig. 19: step 4). 
 
 
 
 
              
 
 
                 
Figure 19: Gene disruption strategy by Datsenko and Wanner in S. flexneri BS176115 
H1 and H2 refer to the homology extensions or regions. P1 and P2 refer to priming sites. 
 
Subsequently the 200 kb virulence plasmid pWR100 of S. flexneri M90T was isolated. After 
that this virulence plasmid and the helperplasmid pCP20116, carrying an antibiotic-resistance, 
were transformed in the already constructed S. flexneri BS176ΔaroA strain. 
After this double transformation the antibiotic-resistant colonies were screened for the 
virulence plasmid pWR100 (Fig. 20) and for the aroA-knockout (Fig. 21). This strain was 
termed S. flexneri M90TΔaroA. 
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Gel:  1. 1 kb Marker 
 2. DSM 21058 
 3. M90TΔaroA clone 1 
 4. M90TΔaroA clone 2 
 5. M90T 
            6. BS176 
            7. BS176ΔaroA 
 
 
Figure 20: PCR for pWR100 
PCR for pWR100 was done with primers pWR100_up and pWR100_down, The two primers are located in the 
ics-Gen, coded by the virulence plasmid pWR100. Strains harboring pWR100 show a 635 bp product (DSM 
21058, M90T, M90TΔaroA) 
 
A strain haboring the virulence plasmid pWR100 was detected by a 635 bp product as seen 
for the constructed S. flexneri M90TΔaroA, the strain DSM 21058 and the wt S. flexneri M90T 
The latter were used as positive controls (Fig. 20). 
Subsequently we performed PCR reactions to detect bacteria with aroA-deletion (Fig. 21). 
 
 
Figure 21: PCR for aroA knockout 
PCR for aroA-gene knockout was done with primers AroAFr_up and AroAFr_down. The product of aroA wt 
gene was 1800 bp (M90T, BS176). An aroA knockout was detected by a 600 bp product (M90TΔaroA, 
BS176ΔaroA) 
 
The product of aroA wt gene was 1800 bp detected for S. flexneri M90T and S. flexneri BS176 
(Fig. 21). An aroA knockout was detected by a 600 bp product as seen for the constructed S. 
flexneri M90TΔaroA, S. flexneri BS176ΔaroA and the strain DSM 21058 (Fig. 21). 
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V.5. In vitro experiments  
 
V.5.1. In vitro characterization of S. flexneri aroA-mutants 
After the construction of the aroA-mutants, the strains were characterized with respect to 
extracellular and intracellular growth, early association, invasion and cell-to-cell spread in 
vitro.  
 
V.5.1.1. Extracellular growth of aroA-mutants 
Extracellular growth was determined at 37 °C at 180 rpm in LB medium. OD was measured 
every hour (Fig. 22). 
 
 
Figure 22: Extracellular growth of S. flexneri aroA-mutants 
Determination of the growth rates at 37 °C at 180 rpm in LB medium. The overnight-culture was diluted 1:20 for 
the main culture and OD was measured every hour. Bars represent means +/- SD of three different experiments. 
 
The plasmidless avirulent strain S. flexneri BS176 was characterized by a maximal growth 
rate of 0.3 OD/h in LB medium, whereas the virulent strain S. flexneri M90T had a slightly 
reduced maximal growth rate of 0.2 OD/h (Fig. 22), which might be explained by the 
presence of the large virulence plasmid pWR100. As expected, strains carrying aroA 
mutations had substantially reduced maximal growth rates. S. flexneri M90TΔaroA had a 2.5 
fold slower maximal growth rate than wt S. flexneri M90T. Again, S. flexneri BS176ΔaroA 
had a slightly higher maximal growth rate compared to S. flexneri M90TΔaroA.  
 
V.5.1.2. Early association, invasion and intracellular replication of aroA-mutants 
Subsequently, we investigated the contribution of the aroA-mutation with respect to early 
association, invasion and intracellular replication (Fig. 23). 
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Figure 23: Early association, invasion and intracellular replication of aroA-mutants 
(a) Invasion assay with HeLa cells. Cells were infected at a MOI of 100. 35 min i.(association) and 1 h p.i. 
(invasion), the CFUs were determined relative to the wt strain M90T. (b) To determine the intracellular 
replicatory potential, cells were infected with an MOI of 100:1 for 1 h. Subsequently, cells were incubated for 
additional 2 hours in the presence of gentamicin and the CFU of lysed cells was determined. Bars represent 
means +/- SD of three different experiments. ***: p < 0,001, Student`s t-test. 
 
As depicted in figure 23a, the strain S. flexneri M90TΔaroA showed no significant difference 
in its rate of association and invasion relative to the wt strain S. flexneri M90T. In contrast, S. 
flexneri BS176ΔaroA was attenuated in its invasion behavior as expected. The wt S. flexneri 
M90T showed a 12 fold higher intracellular replication rate than the aroA-mutants in the time 
period of 2 h (Fig. 23b). These data show that the strain S. flexneri M90TΔaroA is strongly 
attenuated in its intracellular replication.  
 
V.5.1.3. Intercellular spreading of aroA-mutants 
 
V.5.1.3.1. L-Top agar assay 
Because of the defect in intracellular replication of the aroA-mutants, cell-to-cell spread is 
difficult to assess with a conventional assay. Therefore we developed a new spreading assay, 
which is less sensitive for intracellular replication (Fig. 24).  
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Figure 24: Intercellular spreading of aroA-mutants determined by L-Top agar assay 
(a) Experimental schedule of L-Top agar assay. (b) To determine the ability of intercellular spreading, HeLa 
cells were infected for 1 h at a MOI of 500:1. After that the infected cells were irradiated at 20 Gray to block the 
replication of the HeLa cells. The infected, irradiated Hela cells were co-incubated with non-infected HeLa cells 
in a ratio of 70:1 for 2 h, 8 h and 12 h in the presence of gentamicin. Subsequently, serial dilutions of non-lysed 
cells in SeaPlaque agarose, were plated on BHI agar plates. Due to massive cell death upon infection the 12 h 
time point could not be assessed for the wt. Bars represent means +/- SD of three different experiments. 
 
In the first step, HeLa-cells were infected for 1 h at a high MOI of 500 (Fig. 24). 
Subsequently, the infected cells were irradiated to block the replication of the HeLa cells. The 
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infected, irradiated Hela cells were co-incubated on a monolayer of non-infected HeLa cells 
in a ratio of 1:70 in the presence of gentamicin. The number of infected cells was determined 
by plating on SeaPlaque agarose avoiding cell lysis. The wt S. flexneri M90T showed an 
increase in the number of infected cells by a factor of 12 after 8 h. At later time points, the 
non-attenuated, virulent strain was toxic for the cells and CFU determination was no more 
possible. In the case of S. flexneri M90TΔaroA, the increase of the number of infected cells 
was 6 fold after 8 h and 17 fold 12 h after co-infection, whereas the number of infected cells 
for the avirulent strain S. flexneri BS176ΔaroA increased by only 3 fold after 8 h and showed 
no further increase until 12 h. These results suggest a non-impaired potential of S. flexneri 
M90TΔaroA for cell-to-cell spread. The small increase observed for S. flexneri BS176ΔaroA, 
which does not carry the genetic information for cell-to-cell spread might be due to partial cell 
lysis at early time points of the highly infected irradiated cells with an only partial killing of 
extracellular bacteria by the rather low gentamicin concentration of only 10 µg/ml for 12 h in 
order to protect the eukaryotic cells. 
 
V.5.1.3.2. Giemsa staining 
To study intracellular multiplication and behavior of cell-to-cell spreading, we also performed 
Giemsa staining of Shigella-infected cells. Briefly, HeLa cells were infected at a MOI of 100 
for 1 h. Time points of 1 h and 4 h p.i. were examined (Fig. 25).  
 
Figure 25: Giemsa staining 
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HeLa cells were infected with Shigella flexneri M90T (M90T), Shigella flexneri M90TΔaroA (M90TΔaroA) or 
Shigella flexneri BS176ΔaroA (BS176ΔaroA) for 1 h and 4 h  p.i. Subsequently cells were fixed and stained with 
Giemsa dye. Scale bars represent 50 µm. 
 
The Giemsa stainings of HeLa cells infected with wt S. flexneri M90T or S. flexneri 
M90TΔaroA 4 h p.i. showed regions of cell-to-cell spread (Fig. 25, indicated with arrows) in 
contrast to HeLa cells infected with S. flexneri BS176. 
 
V.5.2. In vitro caspase-1 activation and induction of apoptosis by Shigella 
aroA-mutants 
V.5.2.1. Western Blot analysis 
To determine the capacity of the aroA-mutants to activate caspase-1 (Fig. 26a) and to induce 
apoptosis (Fig. 26b) in vitro, J774A.1 mouse macrophages were infected and cellular lysates 
were analyzed by Western Blotting analysis at different time points using an anti-caspase-1 
antibody recognizing the active 20 kDa fragment of activated caspase-1 (Fig. 26a, caspase-1*) 
and an anti-PARP antibody recognizing the cleaved 85 kDa fragment (Fig. 26b, cPARP).  
 
Figure 26: Western Blot analysis of S. flexneri aroA-mutants for caspase-1 activation 
and PARP cleavage 
To determine the capacity of the aroA-mutants to induce caspase-1 activation and apoptosis, J774A.1 mouse 
macrophages were infected with S. flexneri M90T (M90T), S. flexneri M90TΔaroA (M90TΔ) and S. flexneri 
BS176 (BS176Δ) for 1 h and 2 h p.i. and cellular lysates were analyzed by Western Blot at different time points 
using an anti-caspase-1 antibody recognizing the active 20 kDa fragment of caspase-1 (a, caspase-1*)  and an 
a 
b 
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anti-PARP antibody recognizing the cleaved 85 kDa fragment (b, cPARP). Apoptosis induction and caspase-1 
processing by M90TΔ was completely blocked by the caspase-1 specific inhibitor YVAD-CHO (2,5 mM). Β-
Actin was used as loading control.  
 
S. flexneri M90TΔaroA, but not S. flexneri BS176ΔaroA, was able to induce both caspase-1 
processing and apoptosis. Of note, apoptosis induction by S. flexneri M90TΔaroA was 
caspase-1 dependent, as the caspase-1 specific inhibitor YVAD-CHO fully blocked caspase-1 
and PARP processing (Fig. 26a, b). 
 
V.5.2.2. Hoechst 33342 staining 
For further investigation whether the strain Shigella flexneri M90TΔaroA is able to induce 
apoptosis in macrophages we also performed an infection of J774A.1 mouse macrophages 
with the S. flexneri M90TΔaroA strain for 2 h. After that the cells were stained with Hoechst 
33342 dye (Fig. 27). 
 
 
 
 
a) Untreated J774A.1 
          (negative control) 
b) J774A.1 treated with staurosporine for 6h 
(positive control) 
 
 
c) J774A.1 infected with S. flexneri M90TΔaroA (2 h p.i.) 
Figure 27: Hoechst 33342 staining of S. flexneri M90TΔaroA-infected macrophages 
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J774A.1 macrophages were infected with S. flexneri M90TΔaroA for 1 h at a MOI of 100. After that cells were 
washed three times with PBS and incubated for 1 h with 100 µg/ml gentamicin. Subsequently macrophages were 
incubated for 1 h with 50 µg/ml gentamicin. As positiv control for apoptosis induction macrophages were 
incubated with 4 µmol/l staurosporine for 6 h (b). Not infected J774A.1 macrophages were used as negativ 
control (a).  
 
Figure 27a shows healthy untreated macrophages. There are light blue dots which indicate the 
heterochromatin in the nuclei. In figure 27c the macrophages were infected with the S. 
flexneri M90TΔaroA strain. Phenotypically, S. flexneri M90TΔaroA-infected macrophages 
display common indicators of apoptosis such as nuclear fragmentation (which leads to the 
replacement of the heterochromatin to the plasma membrane) and cells in the later 
morphological stages of apoptosis for example with membrane blebbing. So the S. flexneri 
M90TΔaroA strain is able to induce apoptosis in macrophages. In figure 27b the macrophages 
were treated with staurosporine as a positive control for apoptosis. 
 
V.5.3. In vitro activation of caspase-1 by S. typhimurium ΔaroA and S. 
flexneri strains 
 
Within macrophages, bacteria like Salmonella and Shigella can survive using distinct 
virulence mechanisms and can induce apoptosis of the infected macrophages through 
activation of caspase-1 mediated by IpaB (Shigella) or SipB (Salmonella)17,18. In our study the 
strain S. typhimurium ΔaroA was used as a control.  
RAW 264.7 macrophages were infected at a MOI of 10 with S. typhimurium ΔaroA 
(stationary growth phase), S. flexneri M90T and S. flexneri M90TΔaroA (both mid-logarithmic 
growth phase) for different time points. Subsequently, Western Blot analysis for caspase-1 
activation of the cell lysate was performed (Fig. 28). 
 
 
Figure 28: In vitro activation of caspase-1 by S. flexneri M90TΔaroA 
RAW 264.7 macrophages were infected at a MOI of 10 for 1 h with S. flexneri M90T (M90T, mid-logarithmic 
growth phase), S. flexneri M90TΔaroA (M90TΔ, mid-logarithmic growth phase) and S. typhimurium ΔaroA 
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(StmΔ, stationary growth phase) for different time points. After an incubation of 1 h with 100 µg/ml gentamicin 
and additional 1-2 h with 10 µg/ml gentamicin, the different samples were prepared for Western Blot analysis. 
The antibody detects the activated caspase-1 20 kDa subunit (caspase-1*). GAPDH was used as loading control. 
 
The Shigella strain encompassing the aroA deletion showed a slight delay in caspase-1 
activation but reached the same activity 2 h p.i. as compared to the wt S. flexneri M90T strain. 
The Salmonella strain induced caspase-1 processing 3 h p.i. (Fig. 28). 
 
V.5.3.1. In vitro activation of caspase-1 by S. typhimurium ΔaroA is growth 
phase dependent 
 
During an infection with Salmonella a gene expression switch from the SPI1 to the SPI2 
pathogenicity island occurs, which is the natural sequence after oral infection. One 
consequence of this switch is the shutdown of the SipB expression and secretion via the SPI1 
encoded type 3 secretion system, which leads to a substantial reduction in caspase-1 induced 
apoptosis at later time points of infection18.  
To investigate that caspase-1 activation by S. typhimurium ΔaroA is growth phase dependent, 
RAW 264.7 macrophages were infected at a MOI of 10 with S. flexneri M90T, S. flexneri 
M90TΔaroA (both mid-logarithmic growth phase) and S. typhimurium ΔaroA from stationary 
and from mid-logarithmic growth phase for different time points. Subsequently, Western Blot 
analysis for caspase-1 activation of the cell lysate was performed (Fig. 29). 
 
 
 
Figure 29: In vitro activation of caspase-1 by S. typhimurium ΔaroA 
RAW 264.7 macrophages were infected at a MOI of 10 for 1 h with S. flexneri M90T (M90T, mid-logarithmic 
growth phase), S. flexneri BS176 (BS176, mid-logarithmic growth phase), S. typhimurium ΔaroA (log. StmΔ: S. 
typhimurium ΔaroA grown to mid-logarithmic growth phase) and S. typhimurium ΔaroA (stat. StmΔ: S. 
typhimurium ΔaroA grown to stationary growth phase) for different time points. After an incubation of 1 h with 
* 
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100 µg/ml gentamicin and additional 2-3 hours with 10 µg/ml gentamicin, the different samples were prepared 
for Western Blot analysis. The antibody detects caspase-1 zymogen of 45 kDa and the activated caspase-1 20 
kDa subunit (caspase-1*). GAPDH was used as loading control. 
 
Salmonella strains harvested in logarithmic phase did not induce caspase-1 processing in this 
assay even 4 h p.i., in contrast to Salmonella strains harvested in stationary growth phase (Fig. 
29). For all subsequent infection experiments, Salmonella strains harvested in stationary 
growth phase were used. 
 
V.6. Gentamicin assays 
 
To avoid re-infection of cells during MACS® separation and to assess the number of 
extracellular bacteria, these have to be killed or substantially reduced during an incubation 
time of 1 h. To assess the optimal concentration, the gentamicin assay was performed at 
different concentrations (Fig. 30). 
 
 
Figure 30: Assays to determine maximal gentamicin concentration  
(a) In the first assay 1 x 106 S. typhimurium ΔaroA were treated for ½ h, 1 h and 2 h with 50, 100, 200 and 300 
µg/ml gentamicin and CFU was determined by plating serial dilution on LB agar plates. (b) In the second 
gentamicin assay J774A.1 macrophages were infected with 1 x 106 S. typhimurium ΔaroA (logarithmic growth 
phase). Bacteria were washed three times with DMEM medium and zetrifuged for 10 min at 20,000 x g at 4 °C. 
After 1 h infection, cells were incubated for 1 h with 50, 100, 200 and 300 µg/ml gentamicin followed by a 1 h 
incubation with 10 µg/ml gentamicin after washing with 1 x PBS. CFU was determined after cell lysis by plating 
serial dilutions on LB agar plates. 
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As depicted in figure 30a 1 h incubation with 50, 100 or 200 µg/ml gentamicin led to a 3 fold, 
10 fold or 100 fold reduction of the CFU compared to untreated control (without gentamicin). 
In contrast, incubation with 300 µg/ml reduced free bacteria >1000 fold after 1 h incubation 
and fully eliminated the bacteria after 2 h.  
To determine the effect of this concentration on intracellular bacteria, a similar protocol as 
used for cell separation was employed (Fig. 30b). Macrophages were infected with S. 
typhimurium ΔaroA for 1 h. Subsequently cells were incubated for 1 h with 50, 100, 200 and 
300 µg/ml gentamicin followed by 10 µg/ml gentamicin for 1 h. CFU was determined after 
cell lysis by plating serial dilutions on LB agar plates . 
Doses between 100 – 300 µg/ml gentamicin showed a slightly, 1.5 fold increased bactericid 
activity compared to the 50 µg dose which is marginally active on extracellular bacteria with 
this short incubation time. In between the doses of 100 – 300 µg/ml gentamicin, there is no 
significant difference on intracellular CFU. Therefore, the highest dose of 300 µg/ml 
gentamicin was chosen for future experiments which lead to > 1000 fold reduction of 
extracellular bacteria in the experimental setting employed for cell separation and did not 
exhibit a different activity on intracellular bacteria as compared to the dose of 100 µg/ml as 
suggested in the literature122,123. 
Finally gentamicin activity on S. typhimurium ΔaroA was assessed at different temperatures 
(Fig. 31). 
 
 
Figure 31: Effect of gentamicin at different temperatures 
1 x 106 (CFU) S. typhimurium ΔaroA were incubated overnight at 4, 25 and 37 °C. Next day CFU was 
determined by plating serial dilutions on LB agar plates. 
 
As depicted in figure 31, gentamicin had a reduced activity at 25 °C and no activity at 4 °C. 
Therefore, preparations containing bacteria have to be pre-incubated at 37 °C for 1 h to 
effectively kill the major part of extracellular bacteria.  
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V.7. Purity control of cell separation schedule 
 
V.7.1. Light microscopic analysis 
To evaluate the efficacy of the cell separation which could influence the results with respect 
to the number of infected cells, light microscopic analysis of the three different cell fractions 
were performed (Fig. 32).  
 
 
Figure 32: Light microscopic analysis of the three cell fractions after cell separation 
 
The left panel in figure 32 shows the total tumor cell fraction. In the middle the separated 
macrophages are depicted. The right panel represents the macrophage-depleted fraction. The 
cells of all fractions mainly appear as single cells.  
 
V.7.2. FACS analysis 
After tumor removal and separating of total tumor cells by 0,001 % DNAse and 2 µg/ml 
dispase treatment, cell separation was performed using MACS®. To control the purity of the 
three cell fractions FACS analysis were performed (Fig. 33). Therefore cells were stained 
with an anti-CD11b-FITC, anti-F4/80-PE (Fig. 33) and anti-Gr-1-PE antibody (Fig. 34).  
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Figure 33: Control of cell fraction purity by FACS analysis 
(a) FSC (forward scatter) – SSC (side scatter) dot blot of tumor cell suspension. Gating of tumor cell suspension 
and classification of live cells as population R1. Cell size and complexity affect the relative forward scatter and 
side scatter of incident light, respectively, which are presented in arbitrary units on a linear scale. Each dot 
represents the FSC and SSC value for a single tumor cell. (b, c, d) To control the purity of cell fractions after 
MACSing, cells were double stained with an anti-CD11b-FITC and anti-F4/80-PE antibody. Subsequently 
FACS analysis were performed. This figure shows one representative experiment out of seven. Up to 31 % 
macrophages were detected in the total cell fraction classified as R1 (b). After MACS® separation, the 
macrophage fraction showed a purity of 95 % (c) and no macrophages were detectable in the macrophage-
depleted fraction (d). 
 
The purity of the macrophages fraction is between 95–99 % (n = 7). Note that the macrophage 
fraction (Fig. 33c) contains a substantially lower amount of cells compared to the macrophage 
depleted (Fig. 33d) fraction.  
For purity control the macrophage fraction and the magrophage-depleted fraction were also 
stained by an anti-CD11b-FITC and an anti-Gr-1-PE antibody, because we define our TAMs 
as F4/80+, CD11b+ and Gr-1– (Fig. 34). Gr-1 is a cell surface marker of granulocytes. 
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Fiure 34: Purity control of the macrophages fraction 
For purity control the macrophages fraction (a, b) and the macrophage-depleted fraction (c, d) were also stained 
by an anti-CD11b-FITC and an anti-Gr-1-PE antibody (bottom panels). This figure shows one representative 
experiment out of seven. 
 
As figure 34 shows, the number of Gr-1+ cells in the macrophages fraction was between 
0,01 – 0,03 % (Fig. 34b). So the degree of purity in the macrophages fraction was around 99 
%. In addition we showed that TAMs do not express Gr-1 (Fig. 34b). In the macrophage-
depleted fraction we detected up to 53 % Gr-1 and CD-11b double positive granulocytes (Fig. 
34d). Whereas only few macrophages (around 2 %) were detectable in this fraction (Fig. 34c). 
 
V.8. Ex vivo experiments 
 
In this experimental setup tumor tissue from tumor-bearing Balb/c (Fig. 35a, b), or female 
MMTV-HER2 mice (Fig. 36a, b) were excised and separated. 1 x 106 cells per fraction were 
seeded in a 6-well-plate. After 3 h the different cell fractions were infected with the three 
different Shigella strains: S. flexneri M90T, S. flexneri M90TΔaroA and S. flexneri 
BS176ΔaroA. After an incubation of 1 h with 300 µg/ml gentamicin some samples were 
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prepared for Western Blot analysis (Fig. 35 and 36) and serial dilutions of the other samples 
were plated onto agar plates to determine CFU (Fig. 37). 
 
V.8.1. Ex vivo activation of caspase-1 
To investigate whether there is an activation of caspase-1 and an induction of apoptosis after 
an ex vivo infection, the three different cell fractions isolation from tumor-bearing Balb/c (Fig. 
35) or MMTV-HER2 mice (Fig. 36) were infected with S. flexneri M90T, S. flexneri 
M90TΔaroA and S. flexneri BS176ΔaroA at a MOI of 100 for 1 h and Western Blot analysis 
was performed (Fig. 35 and 36). 
 
 
Figure 35: Ex vivo infection of separated 4T1-induced tumor cell fractions with Shigella 
strains 
(a, b) Ex vivo infection of the three different cell fractions after cell isolation from tumor-bearing Balb/c mice 
with S. flexneri M90T, S. flexneri M90TΔaroA and S. flexneri BS176ΔaroA at a MOI of 100 for 1 h. After an 
incubation of 1 h with 300 µg/ml gentamicin the different samples were prepared for Western Blot analysis. The 
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antibody detects the procaspase-1 (45 kDa) and the activated caspase-1 20 kDa subunit (a, caspase-1*). The 
PARP antibody detects the cleaved PARP fragment of 85 kDa (b, cPARP). Cells were incubated with 
staurosporine (4 µM) for 6 h as positive control for apoptosis induction. β-Actin was used as loading control. 
 
 
 
Figure 36: Ex vivo infection of separated MMTV-HER2 breast tumor cell fractions with 
Shigella strains 
(a, b) Ex vivo infection of the three different cell fractions after cell isolation from MMTV-HER2 mice (c, d) 
with S. flexneri M90T, S. flexneri M90TΔaroA and S. flexneri BS176ΔaroA at a MOI of 100 for 1 h. After an 
incubation of 1 h with 300 µg/ml gentamicin the different samples were prepared for Western Blot analysis. The 
antibody detects the procaspase-1 (45 kDa) and the activated caspase-1 20 kDa subunit (a, caspase-1*). The 
PARP antibody detects the cleaved PARP fragment of 85 kDa (b, cPARP). Cells were incubated with 
staurosporine (4 µM) for 6 h as positive control for apoptosis induction. β-Actin was used as loading control. 
 
M90T, M90TΔaroA (M90TΔ) but not BS176ΔaroA (BS176Δ) induced caspase-1 processing 
and apoptosis in macrophages isolated from 4T1-induced Balb/c breast tumors (Fig. 35) and 
spontaneous breast adenocarcinomas from transgenic MMTV-HER2/new FVB mice (Fig. 36) 
ex vivo. The macrophage-depleted fractions do not contain procaspase-1 in detectable levels. 
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V.8.2. Determination of CFU after ex vivo infection with Shigella 
In the next experiment we wanted to investigate whether Shigella flexneri M90TΔaroA 
predominantly infects TAMs derived from freshly isolated breast tumors from 4T1-induced 
tumor-bearing Balb/c mice ex vivo (Fig. 37). 
 
 
Figure 37: Determination of CFU after ex vivo infection of separated tumor cell fractions 
with Shigella strains 
Tumor cells were separated and TAMs were isolated as described before. 1 x 106 cells of each cell fraction were 
seeded for 3 h. Subsequently the different cell fractions were infected ex vivo with wt S. flexneri M90T (M90T), 
S. flexneri M90TΔaroA (M90TΔ) and S. flexneri BS176ΔaroA (BS176Δ) at a MOI of 100. After 1 hour of 
infection, cells were incubated for 1 h with 300 µg/ml gentamicin followed by 1 h incubation with 50 µg/ml 
gentamicin. Subsequently, CFU was determined. All results shown are mean ± SD of two samples. Splenocytes 
were used as a control. 
 
S. flexneri M90TΔaroA effectively infected TAMs isolated from 4T1-induced tumor-bearing 
Balb/c mice (Fig. 37). Again, infection of TAMs was at least 100 fold more efficient 
compared to the macrophage-depleted fraction. These results lead to the question whether 4T1 
breast tumor cells generally can be infected by S. flexneri M90TΔaroA. 
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V.8.3. Determination of CFU after in vitro infection of 4T1 cells with 
Shigella 
 
To investigate the ability of S. flexneri M90T to infect and invade 4T1 epithelial cells in vitro, 
we performed some invasion and survival assays (Fig. 38) 
 
 
Figure 38: In vitro infection of 4T1 cells with S. flexneri M90T 
Invasion and survival assay with 4T1 cells to determine the grade of infection. 2 x 105 cells were infected at a 
MOI of 100 with S. flexneri M90T and S. flexneri BS176 for 1 h p.i. (invasion), 2 h p.i. and 3 h p.i. (survival). 
Subsequently CFUs and the grade of infection were determined. Bars represent means +/- SD of four different 
experiments. 
 
As depicted in figure 38, the strain S. flexneri M90T showed at 1 h p.i. about 3 fold higher 
grade of infection in comparison to the non-invasive strain S. flexneri BS176. These data show 
that the strain S. flexneri M90T is able to invade non-phagocytic epithelial cells like 4T1 
breast cancer cells. Moreover S. flexneri M90T is able to survive and replicate intracellularly.  
 
V.9. In vivo experiments 
 
After our ex vivo experiments we wanted to determine whether S. flexneri M90TΔaroA also 
effectively infects TAMs and activates caspase-1 in vivo. 
 
V.9.1. Determination of CFU and infected cell number 
In this set of experiments, we wanted to investigate the quantitative distribution of Shigella 
and Salmonella in the extracellular and intracellular compartment of different breast tumor 
models, as well as different cell types of the tumor tissue. Therefore 1 x 106 Salmonella 
typhimurium ∆aroA (Salmonella typhimurium ∆aroA, Stm∆), Shigella flexneri BS176ΔaroA 
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(BS176Δ) and Shigella flexneri M90TΔaroA (M90TΔ) were applied intravenously in mice 
with established 4T1 tumors (Fig. 39 and 40) or spontaneous MMTV-HER2/new breast 
carcinoma (Fig. 41 and 42). 
Therefore tumors were removed at different time points after infection. Tumor cells were 
separated to obtain a tumor cell suspension. Pools of the tumor cell suspension were treated 
with gentamicin to distinguish extra- and intracellular bacteria. In parallel, cells were 
separated in macrophages and macrophage-depleted fractions to analyze the bacterial content. 
The cell number of every cell fraction was determined by a Bürker cell chamber. Plating was 
performed either after lysis of the eukaryotic cells to determine total CFU titers, or by plating 
in L-Top agar avoiding cell lysis to determine the number of infected cells (Fig. 39, 40, 41 
and 42). 
 
V.9.1.1. Determination of CFU and infected cell number after infection with S. 
typhimurium ΔaroA in the 4T1-induced tumor model 
1 x 106 Salmonella typhimurium ∆aroA (Salmonella typhimurium ∆aroA, Stm∆) were applied 
intravenously in mice with established 4T1 tumors and quantitative distribution of these 
bacteria was investigated in the extracellular and intracellular compartment of this breast 
tumor model (Fig. 39). 
 
 
 
Figure 39: Salmonella predominantly target TAMs in Balb/c mice at early time points 
V. Results  92  
Determination of CFU (a), infected cell number (b), CFU/cell number (c) and infected cells/cell number (d) of 
separated tumor cells and splenocytes as a control 6 h and 7 d after i.v. infection of tumor-bearing mice (n = 3 
mice per group and time point) with 1 x 106 S. typhimurium ΔaroA (StmΔ) . CFU was determined by plating 
serial dilutions of cell lysate. Infected cell number were determined by plating non-lysed, gentamicin treated 
cells, in L-Top agar. + describes gentamicin treatment in contrast to – (without gentamicin treatment). All results 
shown are mean ± SD; **: p < 0,01, ***: p < 0,001, Student`s t-test. Detection limits are set up at the highest 
values of counted tumor cell number. 
 
As shown in figure 39, the strain Salmonella typhimurium ΔaroA predominantly targets 
TAMs in vivo after 6 h p.i. 7 d after infection there were only few bacteria detected in the 
spleen, which is in line with previous works132. After 6 h and 7 d significantly more bacteria 
are found in the macrophages fraction compared to macrophage-depleted tumor cells. 4 h and 
6 h after infection, most bacteria are intracellular, whereas 7 d after infection more bacteria 
are found extracellularly as determined by CFU numbers derived from gentamicin treated 
compared to untreated total tumor cells.  
 
V.9.1.2. Determination of CFU and infected cell number after infection with Shigella in 
the 4T1-induced tumor model 
Subsequently we analysed whether Shigella shows a similar preferred targeting of 
macrophages as observed for Salmonella. Therefore, we injected Shigella i.v. in Balb/c mice 
with established 4T1-tumors in a similar setting as performed before for Salmonella (Fig. 40). 
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Figure 40: S. flexneri M90TΔaroA predominantly target TAMs in Balb/c mice 
Determination of CFU (a, c), infected cell number (b, d), CFU/cell number (e, g) and infected cells/cell number  
(f, h) of separated tumor cells and splenocytes as a control 6 h and 7 d after i.v. infection of tumor-bearing 
Balb/c mice (n = 3 mice per group and timepoint) with S. flexneri BS176ΔaroA (BS176Δ) (a, b, e, f) and 
M90TΔaroA (M90TΔ) (c, d, g, h). + describes gentamicin treatment in contrast to – (without gentamicin 
treatment). All results shown are mean ± SD; **: p < 0,01, ***: p < 0,001, Student`s t-test. Detection limits are 
set up at the highest values of counted tumor cell number. 
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Again, significantly more bacteria per cell (Fig. 40e, g) and more infected cells (Fig. 40f, h) 
were found in the macrophages fraction at any time point. Furthermore, the major part of S. 
flexneri M90TΔaroA is found intracellularly (Fig. 40g), whereas 50 fold more bacteria were 
found extracellularly 6 h after infection with the avirulent strain S. flexneri BS176ΔaroA (Fig. 
40e). 
 
V.9.1.3. Determination of CFU and infected cell number after infection with S. 
typhimurium ΔaroA in the MMTV-HER2/new tumor model 
To investigate the exact location of bacteria like Salmonella in a spontaneous tumor model, 
we performed the same experimental setup with transgenic MMTV-HER2/new mice 
(Fig. 41). 
 
 
Figure 41: S. typhimurium ΔaroA (StmΔ) predominantly targets TAMs in transgenic 
MMTV-HER2/new FVB mice 
In vivo infection of tumor-bearing MMTV-HER2/new FVB mice with 1 x 106 Salmonella typhimurium ΔaroA 
(StmΔ) and determination of CFU (a, c) and the number of infected cells (b, d) by L-top agar assay after 6 h. 
Tumor-bearing MMTV-HER2/new FVB mice (n = 4) were infected with Salmonella typhimurium ΔaroA (1 x 
V. Results  95  
106). 6 h p.i. spleens and tumors were removed, cells were separated and gentamicin-treated (+) or not (-). Total 
CFU was determined by plating serial dilutions of lysed cells and the number of infected cells was determined 
by plating of serial dilutions of intact cells in L-Top agar. All results shown are mean ± SD; **: p < 0,01, ***: 
p < 0,001, Student`s t-test.  
 
Similar to the results obtained with transplanted tumors (Fig. 39), Salmonella infected TAMs 
with approximately 100 fold higher efficiency as compared to macrophage-depleted tumor 
cells in a transgenic animal model bearing spontaneous breast adenocarcinoma (Fig. 41a-d). 
Also in this model, the majority of bacteria was intracellular. 
 
V.9.1.4. Determination of CFU and infected cell number after infection with Shigella in 
the MMTV-HER2/new tumor model 
To investigate the exact location of bacteria like Shigella in a spontaneous tumor model, we 
performed the same experimental setup with transgenic MMTV-HER2/new FVB mice 
(Fig. 42). 
 
 
Figure 42: S. flexneri M90TΔaroA (M90TΔ) predominantly targets TAMs in transgenic 
MMTV-HER2 mice 
Determination of CFU (a, c) and the number of infected cells (b, d) by L-Top agar assay after 7 d. Tumor-
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bearing MMTV-HER2/new FVB mice (n = 4) were infected with S. flexneri M90TΔaroA and BS176ΔaroA (1 x 
106). After 7 d p.i. spleens and tumors were removed, and cells were separated. Total CFU was determined by 
plating of serial dilutions of lysed cells and the number of infected cells was determined by plating serial 
dilutions of intact cells in L-Top agar. All results shown are mean ± SD; **: p < 0,01, ***: p < 0,001, Student`s t-
test. Detection limits are set up at the highest values of counted tumor cell number. 
 
S. flexneri M90TΔaroA predominantly resided in macrophages of tumor-bearing mice with 
spontaneous breast adenocarcinoma (5 fold difference compared to macrophage-depleted 
fraction) 7 d p.i. (Fig. 42). The non-invasive S. flexneri BS176∆aroA strain was still present in 
the tumors with very low bacteria numbers and also found predominantly in macrophages.  
 
V.9.2. Kinetics of bacterial tumor colonization 
To determine the kinetics of tumor colonization 1 x 106 S. flexneri M90T∆aroA and S. flexneri 
BS176∆aroA were applied intravenously in mice with established 4T1 tumors and 
quantitative distribution of these bacteria was investigated in the extracellular and intracellular 
compartment of this breast tumor model after 1 d, 3 d and 7 d p.i. (Fig. 43). 
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Figure 43: Kinetics of tumor targeting by Shigella in tumor-bearing Balb/c mice 
Determination of CFU/cell number after 1 d, 3 d and 7 d p.i. 4T1-induced tumor-bearing Balb/c mice (n = 4) 
were infected with 1 x 106 S. flexneri M90TΔaroA (a) and BS176ΔaroA (b). After 1 d, 3 d and 7 d p.i. spleens 
and tumors were removed, and cells were separated. Total CFU was determined by plating of serial dilutions of 
lysed cells. + describes gentamicin treatment in contrast to – (without gentamicin treatment). All results shown 
are mean ± SD. 
 
Again, significantly more bacteria per cell were found in the macrophages fraction at any time 
point (Fig. 43a, b). Furthermore, the major part of S. flexneri M90TΔaroA is found 
intracellularly at 1 d, 3 d and 7 d p.i. (Fig. 43a), whereas some bacteria were found 
extracellularly at all time points after infection with the avirulent strain S. flexneri 
BS176ΔaroA (Fig. 43b). 
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V.9.3. Caspase-1 activation and induction of apoptosis in vivo 
Afterwards we asked whether there is an induction of apoptosis in the macrophages via 
caspase-1 activation by secreted SipB (Salmonella) or IpaB (Shigella) in vivo. Therefore we 
analysed the cell populations for caspase-1 activation and induction of apoptosis after 
infection with Salmonella typhimurium ∆aroA (Fig. 44) and Shigella (Fig. 45 and 46). 
 
V.9.3.1. Caspase-1 activation and induction of apoptosis by S. typhimurium ΔaroA in the 
4T1-induced tumor model 
After infection of 4T1-induced tumor-bearing mice with Salmonella, caspase-1 activation and 
PARP cleavage of separated and lysed tumor cells was analyzed by Western Blot (Fig. 44).  
 
 
Figure 44: Caspase-1 activation and induction of apoptosis 6 h after infection with S. 
typhimurium ΔaroA 
In vivo infection of tumor-bearing Balb/c mice with 1 x 106 S. typhimurium ΔaroA (StmΔ), tumor cell isolation 
and analysis for caspase-1 activation (a) and induction of apotosis (b). Ex vivo infection with S. flexneri M90T 
for 2 h in tumor-bearing Balb/c isolated TAMs was used as positive control for caspase-1 activation. Incubation 
of tumor-bearing Balb/c isolated TAMs with staurosporine (4 µM) for 6 h was taken as positive control for 
PARP cleavage. The caspase-1 antibody detects the caspase-1 zymogen of 45 kDa and the active 20 kDa 
subunits of caspase-1 (caspase-1*). The PARP antibody detects the cleaved PARP fragment (cPARP) of 85 kDa. 
GAPDH was used as loading control. 
a 
b 
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Caspase-1 activation and PARP cleavage was detected in total cells and macrophages fraction 
of tumors from mice 6 h after infection, but not from 4 h infected mice (Fig. 44). Caspase-1 
activation and PARP cleavage was not detected in the macrophage-depleted fraction, where 
neither caspase-1 processing nor caspase-1 expression was detectable. Caspase-1 induction 
was not detected in any fraction 7 d after Salmonella infection.  
 
V.9.3.2. Caspase-1 activation and induction of apoptosis by S. flexneri M90TΔaroA 
 
V.9.3.2.1. Caspase-1 activation and induction of apoptosis in the 4T1-induced tumor 
model 
In this experimental setup 4T1-induced tumor-bearing Balb/c mice were infected with 
Shigella aroA-mutants for 4 h, 6 h and 7 d. Subsequently caspase-1 activation and PARP 
cleavage of separated and lysed tumor cells was analyzed by Western Blot (Fig. 45).  
 
 
Figure 45: Caspase-1 activation and induction of apoptosis 4 h, 6 h and 7 d after 
infection with S. flexneri M90TΔaroA in tumor-bearing Balb/c mice 
In vivo infection of tumor-bearing Balb/c mice with 1 x 106 S. flexneri M90TΔaroA (M90TΔ) or S. flexneri 
BS176ΔaroA (BS176Δ), tumor cell isolation and analysis for caspase-1 activation (a) and induction of apotosis 
(b). The caspase-1 antibody detects the caspase-1 zymogen of 45 kDa and the active 20 kDa subunits of caspase-
1 (caspase-1*). The PARP antibody detects the cleaved PARP fragment (cPARP) of 85 kDa. GAPDH was used 
a 
b 
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as loading control. Incubation of tumor-bearing Balb/c isolated TAMs with staurosporine (4 µM) for 6 h was 
taken as positive control for PARP cleavage. 
 
Caspase-1 activation (Fig. 45a) and PARP cleavage (Fig. 45b) was detectable in total cells 
and macrophages fraction of tumors taken from mice 4 h and 6 h after S. flexneri M90TΔaroA 
infection, and in the macrophages fraction 7 d after infection with S. flexneri M90TΔaroA, but 
not S. flexneri BS176ΔaroA. 
 
V.9.3.2.1. Caspase-1 activation and induction of apoptosis in the MMTV-HER2/new 
tumor model 
In this experimental setup tumor-bearing MMTV-HER2/new FVB mice were infected with 
Shigella aroA-mutants for 6 h and 7 d. Subsequently caspase-1 activation and PARP cleavage 
of separated and lysed tumor cells was analyzed by Western Blot (Fig. 46). 
 
 
Figure 46: Caspase-1 activation and induction of apoptosis 4 h, 6 h and 7 d after 
infection with S. flexneri M90TΔaroA in MMTV-HER2/new FVB mice 
In vivo infection of tumor-bearing MMTV-HER2/new mice with 1 x 106 S. flexneri M90TΔaroA (M90TΔ) or S. 
a 
 b 
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flexneri BS176ΔaroA (BS176Δ), tumor cell isolation and analysis for caspase-1 activation (a) and induction of 
apotosis (b). The caspase-1 antibody detects the caspase-1 zymogen of 45 kDa and the active 20 kDa subunits of 
caspase-1 (caspase-1*). The PARP antibody detects the cleaved PARP fragment (cPARP) of 85 kDa. GAPDH 
was used as loading control. Ex vivo infection with S. flexneri M90T for 2 h in tumor-bearing Balb/c isolated 
TAMs was used as positive control for caspase-1 activation. Incubation of tumor-bearing Balb/c isolated TAMs 
with staurosporine (4 µM) for 6 h was taken as positive control for PARP cleavage. 
 
Similar to the results obtained with transplanted tumors (Fig. 39), caspase-1 activation and 
induction of apoptosis by Shigella flexneri M90TΔaroA was detected in the total cell fraction 
and in macrophages fraction 4 h, 6 h and 7 d p.i. in transgenic MMTV-HER2 breast tumor 
mice (Fig. 46). In addition caspase-1 activation and PARP cleavage was not detected in the 
macrophage-depleted fraction, where neither caspase-1 processing nor caspase-1 expression 
was detectable. Also caspase-1 induction was not detected in any fraction after infection with 
Shigella flexneri BS176ΔaroA.  
 
V.10. Determination of TAMs number by FACS analysis 
 
In the next set of experiments, 1 x 106 S. typhimurium ∆aroA (Stm∆), S. flexneri BS176ΔaroA 
(BS176∆) and S. flexneri M90TΔaroA (M90T∆) were applied intravenously in mice with 
established 4T1 tumors (Fig. 48) or spontaneous breast carcinoma (Fig. 49). 7 d post infection 
the relative amount of TAMs was determined by FACS analysis (Fig. 47). 
 
 
Figure 47: Determination of TAMs number by FACS analysis 
To control the the number of TAMs 7 d after infection with S. typhimurium ∆aroA (Stm∆), S. flexneri 
BS176∆aroA (BS176∆) and S. flexneri M90T∆aroA (M90T∆) in tumor-bearing Balb/c (Fig. 48) and transgenic 
MMTV-HER2/new FVB (Fig. 49), the relative amount of TAMs was determined by FACS. Cells were double 
stained with an anti-CD11b-FITC and anti-F4/80-PE antibody. Subsequently FACS analysis were performed. 
This figure shows one representative experiment of infection with not infected tumor tissue (a) and tumor tissue 
7 d infected with S. flexneri M90T∆aroA (b). 
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The number of macrophages in the tumor tissue of naïve mice was between 27-35 % (n = 4, 
in the 4T1-induced tumor model) and 30-45 % (n = 3, in the MMTV-HER2/new tumor 
model). Note that the reduction of macrophage number in 7d M90TΔaroA-infected tumor 
tissue was up to 70 % in both breast tumor models (Fig. 47b).  
 
 
Figure 48: Determination of TAMs number in the 4T1-induced tumor model by FACS 
analysis 
7 d after infection with S. typhimurium ∆aroA (a, Stm∆), S. flexneri BS176∆aroA (b, BS176∆) and S. flexneri 
M90T∆aroA (b, M90T∆) in tumor-bearing Balb/c mice, the relative amount of TAMs was determined by FACS. 
Bars represent means +/- SD of four (M90TΔ , BS176Δ) alternatively three (StmΔ) tumors analyzed per group, 
**: p < 0.01, ***: p < 0.001, Students t-test. 
 
 
Figure 49: Determination of TAMs number in the MMTV-HER2/new tumor model by 
FACS analysis 
7 d after infection with S. typhimurium ∆aroA (a, Stm∆), S. flexneri BS176∆aroA (b, BS176∆) and S. flexneri 
M90T∆aroA (b, M90T∆) in tumor-bearing MMTV-HER2/new FVB mice the relative amount of TAMs was 
determined by FACS. Bars represent means +/- SD of four (M90TΔ , BS176Δ) alternatively three (StmΔ) 
tumors analyzed per group, **: p < 0.01, ***: p < 0.001, Students t-test. 
 
S. flexneri M90TΔaroA, but not S. flexneri BS176ΔaroA infection resulted in a substantial 
reduction in macrophage numbers 7 d after infection in both breast tumor models (Fig. 47b, 
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48 and 49). In addition an infection with S. typhimurium ΔaroA did not affect macrophage 
numbers 7 d after infection in both breast tumor models (Fig. 48 and 49).  
 
V.11. Fluorescence staining for cytokeratin 
 
To confirm that epithelial 4T1 cells are positive for cytokeratin we performed some in vitro 
fluorescence staining (Fig. 50).  
 
 
Figure 50: Fluorescence staining for cytokeratin of 4T1 cells in vitro 
4T1 cells (a) and RAW 264.7 (b) macrophages were grown on coverslips for 36 h. Then cells were fixed with 
3.7 % paraformaldehyde and quenched with 10 mM NH4Cl in PBS. The primary antibody anti cytokeratin was 
incubated for 30 min with cells. After several washes with PBS, Tetramethyl Rhodamine Iso-Thiocyanate 
(TRITC)-labeled secondary antibody were diluted in PBS/BSA and incubated with cells for 30 min. Then the 
cells were treated with 0.1 µg/ml Hoechst 33342 dye. At the end cells were covered with Mowiol and subjected 
to fluorescence microscopy. In 4T1 case right panel is the antibody control. Scale bars represent 50 µm.  
 
Staining for cytokeratin revealed that 4T1 breast cancer cells exhibit a characteristic epithelial 
structure (Fig. 50a, red staining) in contrast to RAW 264.7 macrophages, which are 
cytokeratin-negative (Fig. 50b). 
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V.12. Histological examinations 7 d post in vivo infection 
 
To confirm the substantial reduction of macrophage number, which was detected by FACS 
analysis, immunohistological examination of naïve, 7 days S. flexneri BS176ΔaroA- or S. 
flexneri M90TΔaroA-infected Balb/c mice were performed (Fig. 51). 
 
 
 
Figure 51: Histological examinations of tumor tissue 7 d after infection 
Histological examination of naïve (left panels), S. flexneri BS176ΔaroA (BS176Δ, middle panels) and S. flexneri 
M90TΔaroA (M90TΔ, right panels). Besides H&E staining, immunohistological stainings were performed to detect 
macrophages (anti-F4/80 antibody), infiltration of inflammatory cells (anti-CD45 antibody) and cytokeratin (anti-
cytokeratin (CK) antibody) In each case left panels are the antibody controls. Scale bars represent 50 µm. 
 
7d infected mice revealed a substantial reduction of macrophages (Fig. 51, anti-F480 staining) 
and an intense infiltration of inflammatory cells (Fig. 51, anti-CD45 staining). Furthermore, 
cytokeratin staining (Fig. 51, anti-CK staining) of tumors derived from M90TΔaroA-infected 
mice showed a marked reduction in positive cells indicating that cytokeratin positive 
epithelial 4T1 tumor cells are depleted along with the depletion of macrophages. In the naïve 
and BS176ΔaroA-infected tissue no tissue degeneration was detectable and a normal tumor 
rim structure was observed.  
 
V.13. Therapeutic approach 
 
To investigate whether this substantial reduction in macrophage numbers and infiltration of 
inflammatory cells induced by S. flexneri M90TΔaroA is associated with a therapeutic effect, 
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S. flexneri M90TΔaroA or S. flexneri BS176ΔaroA were applied to 4T1-induced tumor-
bearing Balb/c mice and tumor growth was assessed every second day (Fig. 52). 
 
 
 
Figure 52: Infection with S. flexneri M90TΔaroA blocks tumor growth 
(a) 14 days after tumor cell inoculation at a mean tumor volume of 187 mm3, 1 x 106 bacteria were applied i.v. to 
n = 8 mice per group. Naïve and S. flexneri BS176ΔaroA (BS176Δ) infected mice were sacrificed 31 days after 
tumor cell inoculation due to animal welfare reasons. From the S. flexneri M90TΔaroA (M90TΔ)-infected group, 
two mice were sacrificed at day 31 for macroscopic comparison of tumors and 3 mice at day 62 to determine 
CFU and macrophage numbers. ** P < 0.01, *** P < 0.001. At day 66 after tumor cell inoculation, 1 x 106 S. 
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flexneri M90TΔaroA (M90TΔ) were applied i.v. into the remaining 3 mice. On day 82 after tumor cell 
inoculation, CFU in tumor, liver and spleen was determined and the tumor was assessed histologically. (b) 
Histology of tumor tissue from S. flexneri M90TΔaroA (M90TΔ)-infected mice at 82 days after tumor cell 
inoculation (68 days after the first infection). For untreated controls, see Fig. 40. Left panels represent antibody 
controls. Scale bars represent 50 µm. CK: Cytokeratin.  
 
There was a substantial reduction in tumor growth after infection with S. flexneri M90T∆aroA 
(Fig. 52). Of note, tumor growth was completely blocked 19 days after treatment. Infection 
with S. flexneri BS176ΔaroA resulted in a small, albeit significant reduction of tumor growth. 
At day 62 after tumor cell inoculation the non-growing tumors exhibited very low 
macrophage numbers (~4 %) and bacteria were not detectable after CFU determination. At 
day 66 after tumor cell inoculation 1 x 106 S. flexneri M90T∆aroA were applied i.v. to the 
remaining 3 mice. No reduction of tumor size was detected. On day 82 after tumor cell 
inoculation CFU was determined. Bacteria were not detectable in tumor, liver and spleen any 
more. Histological examination of S. flexneri M90TΔaroA 68 d infected mice (at day 82 after 
tumor cell inoculation) revealed still a substantial reduction of macrophages, an intense 
infiltration of inflammatory cells (Fig. 52, anti-CD45 staining) and a complete depletion of 
4T1 tumor cells (Fig. 52, anti-CK staining). 
 
V.14. S. flexneri infection of transgenic SP-C-c-raf BxB-11 mice 
 
V.14.1. Histological examinations of lung tissue 
To investigate whether a treatment with S. flexneri M90T∆aroA would be applicable in 
transgenic SP-C-c-Raf BxB-11 mice with lung tumors, we applied 1 x 106 S. flexneri 
M90T∆aroA i.v. Subsequently we performed histological analysis of lung tissues from control 
C57Bl/6 mice and mice transgenic for lung-targeted expression of SP-C-c-Raf-1-BxB-11 
protein of different age infected with  M90TΔaroA i.v. for 28 d (Fig. 53 – 56). 
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Figure 53: Histological examination of lung tissue 
Lung tissues from naïve 8-month-old C57Bl/6 mouse (a), a 8-month-old C57Bl/6 mouse infected with S. flexneri 
M90TΔaroA (b) and a S. flexneri M90TΔaroA-infected 6-month-old SP-C-c-Raf-1-BxB-11 mouse (c) were fixed 
in paraformaldehyde, embedded in paraffin, sectioned at 4 µm, and stained with H&E after an infection with S. 
flexneri M90TΔaroA for 28 d. Scale bars represent 50 µm. 
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Figure 54: Immunohistological staining of CD45+ cells in lung tissue  
Lung tissues from naïve 8-month-old C57Bl/6 mouse (a), a 8-month-old C57Bl/6 mouse infected with S. flexneri 
M90TΔaroA (b) and a S. flexneri M90TΔaroA-infected 6-month-old SP-C-c-Raf-1-BxB-11 mouse (c) were fixed 
in paraformaldehyde, embedded in paraffin, sectioned at 4 µm, and immunostained with an anti-CD45 antibody 
after an infection with S. flexneri M90TΔaroA for 28 d. In each case left panels represent antibody controls. Scale 
bars represent 50 µm. 
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Figure 55: Immunohistological staining of F4/80+ macrophages in lung tissue 
Lung tissues from naïve 8-month-old C57Bl/6 mouse (a), a 8-month-old C57Bl/6 mouse infected with S. flexneri 
M90TΔaroA (b) and a S. flexneri M90TΔaroA-infected 6-month-old SP-C-c-Raf-1-BxB-11 mouse (c) were fixed 
in paraformaldehyde, embedded in paraffin, sectioned at 4 µm, and immunostained with an anti-F4/80 antibody 
after an infection with S. flexneri M90TΔaroA for 28 d. In each case left panels represent antibody controls. 
Scale bars represent 50 µm. 
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Figure 56: Immunohistological staining of cytokeratin in lung tissue  
Lung tissues from naïve 8-month-old C57Bl/6 mouse (a), a 8-month-old C57Bl/6 mouse infected with S. flexneri 
M90TΔaroA (b) and a S. flexneri M90TΔaroA-infected 6-month-old SP-C-c-Raf-1-BxB-11 mouse (c) were fixed 
in paraformaldehyde, embedded in paraffin, sectioned at 4 µm, and immunostained with an anti-cytokeratin 
antibody after an infection with S. flexneri M90TΔaroA for 28 d. In each case left panels represent antibody 
controls. Scale bars represent 50 µm. 
 
The lung of the C57Bl/6 control mice both, naïve or S. flexneri M90TΔaroA-infected, 
exhibited no tumor tissue (Fig. 53a, b). We observed normal lung tissue containing type I and 
type II pneumocytes and a small number of alveolar macrophages, whereas a small number of 
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infiltrated cells were detectable in the lung of S. flexneri M90TΔaroA-infected C57Bl/6 
control mouse. In addition we detected vascular smooth muscle cells. Here all normal lung 
specimens had a similar staining pattern and a normal structure of bronchial gland cells and 
epithelial cells (surface epithelium, globlet cells). In contrast to that for the 6-month-old SP-
C-c-Raf-1-BxB-11 mouse, the tumor incidence was much higher, resulting in multiple tumor 
foci (Fig. 53 and 56) and immune cell infiltration (Fig. 54). We could not detect any F4/80+ 
macrophages in the lung tissues by F4/80+ staining (Fig. 55).  
In addition we determined the CFU in the lung tissue at 1 d, 7 d, 14 d and 28 d after infection. 
At this time points we did not detect any bateria in the lung.  
 
V.14.2. Infection of SP-C-c-Raf-1-BxB-11 lung cells ex vivo 
To investigate whether a treatment with Shigella flexneri M90TΔaroA would be applicable in 
macrophages of SP-C-c-Raf-1-BxB-11 lung tumors we infected cells derived from freshly 
isolated lung from a SP-C-c-Raf-1-BxB-11 mouse with S. flexneri M90TΔaroA ex vivo 
(Fig. 57). 
 
 
Figure 57: Caspase-1 activation in cell fractions isolated from SP-C-c-Raf-1-BxB-11 
tumor lung cells 
Caspase-1 activation in infected cells was analysed by Western Blot analysis. The antibody detects the 
procaspase-1 (45 kDa) and the activated 20 kDa subunit (caspase-1*). RAW 264.7 macrophages were used as 
positive control. Incubation of RAW 264.7 macrophages with staurosporine (4 µM) for 6 h was used as positive 
control (+). GAPDH was used as loading control. 
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S. flexneri M90TΔaroA effectively induced caspase-1 processing in the total cell fraction, in 
the F4/80+ macrophage-fraction and in the F4/80+ macrophage-depleted fraction (Fig. 57). 
Note that there were less than 0,5 % F4/80+ macrophages detected in SP-C-c-Raf-1-BxB-11 
lung tissue. In the F4/80+ macrophage-depleted cell fraction we also detected procaspase-1 
and activated caspase-1 (caspase-1*) suggesting the remaining of F4/80 weak or F4/80 
negative macrophages in the F4/80+ macrophage-depleted cell fraction. 
 
V.15. S. flexneri infection of human cancer ascites cells 
 
V.15.1. Infection of human cancer ascites cells ex vivo 
To investigate whether a treatment with Shigella flexneri M90TΔaroA would be applicable in 
humans we infected cells derived from freshly isolated ascites from an ovarian carcinoma 
patient with S. flexneri M90TΔaroA ex vivo (Fig. 58). 
 
 
Figure 58: S. flexneri M90TΔaroA (M90TΔ) predominantly targets TAMs isolated from 
human ascites cells ex vivo 
Ovarian cancer ascites contain an adherent (adh.) and a non-adherent (susp.) cellular fraction. Both fractions 
were treated separately with the following protocol. Tumor cells were separated and TAMs were isolated as 
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described before. The different cell fractions were infected ex vivo with wt S. flexneri M90T (M90T), S. flexneri 
M90TΔaroA (M90TΔ) and S. flexneri BS176ΔaroA (BS176Δ) at a MOI of 100. After 1 h of infection, cells were 
incubated for 1 h with 300 µg/ml gentamicin followed by 1 h incubation with 50 µg/ml gentamicin. 
Subsequently, CFU was determined. All results shown are mean ± SD of three samples. ***: p < 0,001, 
Student`s t-test. 
 
S. flexneri M90TΔaroA effectively infected TAMs isolated from human tumors (Fig. 58). 
Again, infection of TAMs derived from a human tumor isolate was at least 100 fold more 
efficient compared to the macrophage-depleted fraction. 
 
V.14.2. Caspase-1 activation and apoptosis induction in human cancer 
ascites cells 
In addition separated cell fractions from isolated human cancer ascites cells were used for 
Western Blot analysis to investigate caspase-1 expression, activation and induction of 
apoptosis (Fig. 59). 
 
 
Figure 59: Caspase-1 activation and apoptosis induction in TAMs isolated from human 
cancer ascites cells 
Caspase-1 activation and PARP processing in infected cells was analysed by Western Blot analysis. The 
antibody detects the procaspase-1 (45 kDa) and the activated 20 kDa subunit. The PARP antibody detects the 
cleaved PARP (cPARP) fragment of 85 kDa. RAW 264.7 macrophages were used as positive control. Incubation 
of total tumor cells isolated from tumor-bearing Balb/c mice with staurosporine (4 µM) for 6 hours was used as 
positive control for cleaved PARP. GAPDH was used as loading control. 
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S. flexneri M90TΔaroA effectively infected TAMs isolated from human tumors (Fig. 58) and 
induced caspase-1 processing and apoptosis in the total cell fraction and in the macrophages 
fraction (Fig. 59). Note that the macrophage-depleted fraction does not contain procaspase-1 
in detectable levels.  
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VI. Discussion 
 
In this work we have demonstrated that pathogenic intracellular bacteria like Salmonella and 
Shigella primarily target TAMs after i.v. infection of tumor-bearing mice both in a 4T1 graft 
and a MMTV-HER2/new transgenic breast cancer model. To determine the behavior of 
Shigella, we constructed an attenuated strain termed S. flexneri M90T∆aroA. This strain 
primarily targeted TAMs in tumor-bearing 4T1 grafted or transgenic MMTV-HER2/new 
mice. In contrast to Salmonella, the Shigella strain was predominantly intracellular at all time 
points and showed a caspase-1 activation and apoptosis induction over the whole observation 
period of 7 days. The sustained apoptosis induction led to a substantial depletion of the TAMs 
and a disruption of TAM clusters in tumors. In contrast, the avirulent strain S. flexneri 
BS176∆aroA and Salmonella had no effect on the macrophage population. Most importantly, 
the macrophage depletion translated into a pronounced therapeutic effect in the 4T1 graft 
model. A single injection of the S. flexneri M90T∆aroA strain resulted in a complete block of 
tumor growth. Approximately two months after treatment, Shigella were no longer detectable 
in the non-growing tumors, whereas TAM numbers were still substantially reduced by a 
factor of 10 compared to values of non-treated animals with similar tumor sizes. Finally, the 
M90T∆aroA strain also efficiently infected TAMs freshly isolated from ascites of a human 
ovarian carcinoma, induced caspase-1 processing and apoptosis in these cells. Therefore, a 
therapy based on the i.v. injection of intracellular bacteria which are capable of sustained 
apoptosis induction might be a worthwhile strategy to follow in future tumor therapy. 
Extracellular bacteria were repeatedly used for experimental tumor therapy1. Their effect in 
different tumor models was explained by the preferential replication in tumors, toxic effects 
on tumor cells by bacterial products and an induction of inflammation1. In our model, we 
aimed primarily at studying intracellular bacteria. However, the avirulent Shigella strain S. 
flexneri BS176∆aroA basically behaves like an extracellular bacterium as it cannot actively 
infect host cells. Our results principally confirm the observation described by others1. At early 
time points like 4 h and 6 h p.i., most of the bacteria are found extracellularly in the tumor. In 
contrast, bacteria isolated from the spleen are found mainly intracellularly. Although we did 
not separate the splenic cell populations, the elimination of systemic bacteria in the spleen is 
normally mediated by phagocytic cells including macrophages133. Our data therefore confirms 
the hypothesis that TAMs have a defect in phagocytosis134,135. At later time points like 7 d 
p.i., S. flexneri BS176∆aroA is also found mainly within macrophages. However, the overall 
number of these metabolically highly attenuated bacteria is very low. These data suggest that 
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phagocytosis in TAMs might still occur, albeit at a much slower rate. Alternatively, different 
TAM populations might exist, including some that have retained the capacity of phagocytosis. 
Interestingly, the treatment with S. flexneri BS176∆aroA resulted in a small, albeit significant, 
therapeutic effect which is in line with recent observations for E. coli strains, that induced a 
measurable inflammatory response but failed to exert a relevant anti-tumor response8. 
Compared to experiments with extracellular bacteria by other authors8,136, our strain carried a 
mutation which blocked intra- and strongly reduced extracellular growth already in rich 
culture medium. Therefore, bacterial numbers were very low seven days after treatment. 
Strong attenuation of bacterial growth may not be the method of choice for a therapy based on 
extracellular bacteria, as it will only result in small numbers of bacteria populating the tumor. 
In addition, bacterial growth could be coupled with impaired phagocytic activity of TAMs 
resulting in the presence of extracellular bacteria at all time points. Such a situation might 
pose the risk of systemic release and consequent septic shock, especially in case of Gram-
negative bacteria. 
For intracellular bacteria, the demonstration that they can transfer DNA into eukaryotic cells 
opened the possibility to deliver therapeutic proteins137. For tumor therapy, it is critical to 
know the target population and the quantitative efficacy of this process. Here we showed for 
the first time, that TAMs are the primary target of intracellular bacteria like Shigella and 
Salmonella in tumors with high numbers of TAMs. In contrast, only a very low portion of 
tumor cells depleted of TAMs are infected. These results question approaches which depend 
on delivering a toxic payload into tumor cells, as it will be difficult to target relevant numbers 
of cells. A possible circumvention might be the use of recombinant bacteria expressing 
molecules allowing a specific uptake of the bacteria by tumor cells. Of note, Salmonella, but 
not Shigella were found mainly extracellularly 7 days after infection, which is in line with the 
qualitative observation from others8. A possible explanation would be a gene expression 
switch from the SPI1 to the SPI2 pathogenicity island within the tumor, which is the natural 
sequence after oral infection60. One consequence of this switch is the shutdown of the SipB 
expression and secretion via the SPI1 encoded type 3 secretion system, which would lead to 
the observed substantial reduction in apoptosis induction at later time points as shown also in 
vitro. In addition, the switch might reduce the induction of active uptake which would result 
in the observed higher numbers of extracellular bacteria in the presence of TAMs with 
impaired phagocytic capacities. 
Our data suggest that the therapeutic effect observed by others using Salmonella7,12,138 may be 
best explained by the induction of inflammation, but not by a depletion or modification of 
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TAMs. One trigger for inflammation might be LPS or bacterial DNA139,140, which could also 
explain the observed limited therapeutic efficacy of the avirulent Shigella strain BS176∆ on 
cancer stem cells. In addition, the physiological consequence of caspase-1 activation is the 
release of IL-1 and IL-18, which are strong pro-inflammatory cytokines. As Salmonella 
activates caspase-1 at early time points (6 h p.i.) , this caspase-1 mediated inflammation might 
contribute to the therapeutic efficacy described by others. However, the clinical efficacy of 
Salmonella was limited, but we can only speculate about the possible reasons. Others have 
already suggested that faster elimination of bacteria from the blood stream in humans leads to 
less efficient tumor targeting of the bacteria limiting the therapeutic efficacy141,142. Based on 
our data, we suggest that a failure to induce relevant levels of caspase-1 triggering an 
inflammatory response might add to the limited efficacy in humans. One of the reasons might 
be the treatment of patients with tumors encompassing only low numbers of TAMs. Another 
reason might be the use of bacteria harvested in the log-phase of growth, which is standard for 
bacteria produced with fermentation. Indeed, Salmonella harvested in the log phase do not 
express the SPI1 pathogenicity island and, as a consequence, do not induce caspase-1 in 
macrophages18. Examining macrophages infected with Salmonella harvested in the log and in 
the stationary phase in vitro, we could confirm that only stationary phase Salmonella induce 
caspase-1 processing. 
In contrast to Salmonella, Shigella do not downregulate their machinery required for caspase-
1 induction after infection. It is well conceivable that virulent Shigella are not suitable for 
therapeutic approaches. In contrast to conventional vaccines, we rely on a fully functional 
virulence apparatus and therefore decided to delete the aroA-locus without modifying 
virulence genes. This Shigella strain showed an apoptosis induction in TAMs at all time 
points like 4 h and 6 h p.i. and resulted in a profound reduction of TAMs which was 
associated with a substantial therapeutic effect in our model. At this point it is difficult to 
decide, whether the observed therapeutic effect was caused by the depletion of TAMs or a 
consequence of inflammation induced by IL-1 and IL-18. However, others have already 
shown that depletion of TAMs is sufficient to block tumor growth in several tumor models 
143. Therefore both factors might contribute to the therapeutic efficacy. Of note, the depletion 
of TAMs is long lasting and persists at late time points, when no more bacteria are present. 
This might be an important factor for a sustained therapeutic efficacy also in the human 
setting, as inflammation will be dependent on the presence of bacteria and therefore transient.  
In this respect it is interesting to compare our data with a most recent work assessing tumor 
targeting in a colon carcinoma model15. In colon carcinoma, macrophages do not seem to play 
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a relevant role in tumor progression and the experimental tumor was instead associated with 
neutrophil invasion, which is in contrast to the 4T1 and HER2/new breast cancer model, 
where Gr-1+ neutrophil numbers were quite low. In this model, the attenuated Shigella strain 
did not reach the tumor after i.v. infection, only intratumoral injection resulted in partial 
necrosis which only had a therapeutic effect after depletion of neutrophils. Therefore, our data 
suggest that both, for targeting and therapeutic efficacy of Shigella, the presence of and the 
dependence on TAMs is important rather than the limited pathogenicity of Shigella in mice, 
as postulated by Weiss. 
Although our data suggest that targeting of tumor cells with Salmonella or Shigella will be 
difficult in tumors with high numbers of TAMs, we consider selective targeting of TAMs as a 
potential advantage. First, TAMs are associated with tumor progression and negative 
prognosis in several human tumors and in mouse models depletion of TAMs has resulted in a 
therapeutic effect. Therefore, TAMs represent a valid target for tumor therapy. Second, 
although TAMs might have a different phenotype compared to macrophages residing outside 
the tumor, they are genetically stable and not transformed144. Therefore, targeting TAMs as a 
part of a tumor-stroma oriented therapy will not face the problems of therapies targeting 
transformed cells bearing a large genetic heterogenity with the risk of escape mutants. Third, 
the data obtained with Shigella imply that already a relatively small number of bacteria in the 
tumor are sufficient for a substantial therapeutic effect which would minimize the risk of 
severe side effects resulting from the systemic release of the bacteria. 
The central question is whether depletion of TAMs by S. flexneri M90TΔaroA resulting in 
tumor growth inhibition can be confered on other tumor models. Tumor-associated 
macrophages in breast cancer have been associated with poor prognosis70. The association 
between TAM and reduced survival has also been shown in renal cell carcinoma145, bladder 
cancer146, prostate cancer147 and lymphoma148. In lung cancer, TAMs may favor tumor 
progression by contributing to stroma formation and angiogenesis through their release of 
PDGF, in conjunction with TGF-ß1 production by cancer cells149. Studies in M-CSF-deficient 
mice (op/op) have provided strong support to the concept of the protumor function of the 
mononuclear phagocyte system. M-CSF deficiency in op/op mice diminishes macrophage 
recruitment, stroma formation and tumor growth in the Lewis lung carcinoma model150. 
However, after i.v. application we could show that S. flexneri M90TΔaroA is not able to target 
the lung tissue of transgenic lung tumor mice. The ex vivo infection showed caspase-1 
activation not only in F4/80+ macrophages isolated from lung tumor tissue but also in F4/80+ 
macrophage-depleted cell fraction after infection with S. flexneri M90TΔaroA. This indicates 
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lung macrophages freshly isolated from transgenic lung tumor mice express mainly other 
surface markers than the F4/80 antigen. It has been reported that an anti-F4/80 antibody did 
not stain lung macrophages in normal mice151. This was in agreement with our results, but 
differs from the results of other authors152,153. The predominant surface phenotype of lung 
macrophages is described as F4/80 weak, Ml/70-, MOMA-2+, NLDC-145+, MOMA-I+, 
SER-4+, which resembles the pattern of expression by lymphoid macrophages rather than 
representative tissue macrophages such as those found in the peritoneal cavity151. This 
indicates that in our F4/80+ macrophage-depleted cell fraction are still F4/80 weak or F4/80- 
macrophages left in which caspase-1 could be activated. 
To our knowledge, immunological studies illustrated the potential of the mouse intranasal 
challenge model for characterization of cellular and humoral immune responses protecting 
against Shigella infection in mucosal epithelia154. The mouse lung can be considered a 
simplified model for the study of the pathogenesis and immunobiology of Shigella infection. 
For example, the pulmonary epithelium in the tracheobronchial tree is simple ciliated 
columnar epithelium with transition to simple cuboidal epithelium in the alveolar sacs155. In 
addition, the bronchial wall contains occasional lymphoid follicles or aggregates of follicles 
that are similar to the Peyer’s patches of the intestine156. Thus, the bronchus constitutes a 
mucosal surface with some characteristics of the intestinal epithelium. Like the intestine, the 
lung is a lymphoid organ with antigen-presenting cells, T helper and suppresser lymphocytes, 
and B lymphocytes156. For this reason intranasal application of Shigella flexneri M90TΔaroA 
might be the best way of application to study the effect of Shigella infection on TAMs of lung 
tumors and their effect on lung tumor growth.  
In summary, we suggest that targeting TAMs using attenuated Shigella or Salmonella with 
additional modification (e.g. a constitutive expression of SPI1) is a promising option for 
future breast tumor therapy. Further studies are required with respect to the safety of the 
Shigella strain and the efficacy of tumor targeting in humans. Furthermore, other intracellular 
bacteria like Listeria157 might be suitable for a macrophage targeted bacterial tumor therapy. 
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VIII.1. List of abbreviations 
 
 
°C degree Celsius 
% per cent 
* in Gaussian distribution 5 cases out of 100 would exhibit this result 
** in Gaussian distribution 1 cases out of 100 would exhibit this result 
*** in Gaussian distribution 1 cases out of 1000 would exhibit this result 
+ positive control 
- negative control (not infected control) 
A Angstroms 
aa amino acid(s) 
Amp Ampicillin 
AmpR Ampicillin resistance 
BHI brain heart infusion 
BS176 Shigella flexneri M90T 
bp, kb base pairs, kilo base pairs 
Caspase-1* activated caspase-1 (p20) 
CD cluster of differentiation 
CFU colony forming units 
CK Cytokeratin 
Cm Chloramphenicol 
CmR Chloramphenicol resistance 
d day 
DAB diaminobenzidin 
dH2O de-ionized water 
EDTA ethylene diamine tetraacetic acid 
Ery Erythromicin 
EryR Erythromicin resistance 
FACS fluorescence activated cell sorting 
fcs foetal calf serum 
FITC fluorescein isothiocyanate 
Flp flipase recombinase 
FRT flipase recombinase target 
g gram 
GAPDH glycerinaldehyd-3-phosphat-dehydrogenase 
Gy Gray 
h hour(s) 
HRP horseradish peroxidase 
IFN interferon 
IL interleukin 
i.v. intravenous 
Kan Kanamycin 
KanR Kanamycin resistance 
kDa kilo Dalton 
l liter 
LB Luria Bertani 
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LD50 lethal dose, 50% 
M molar [mol l-1] 
m meter 
min minute(s) 
MOI multiplicity of infection 
MSZ Institute for Medical Radiation and Cell Research 
M90T Shigella flexneri M90T 
PAGE polyacrylamid-gel-electrophoresis 
PARP poly-ADP-Ribose-Polymerase 1 
cPARP cleaved poly-ADP-Ribose-Polymerase 1 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PE phycoerythrin 
PTP protein tyrosine phosphatase 
rpm revolutions per minute 
RT room temperature 
s second(s) 
s.c. subcutan 
SDS sodium dodecyl sulphate 
SPI-1 Salmonella pathogenicity island 1 
SPI-2 Salmonella pathogenicity island 2 
Stm Salmonella enterica serovar Typhimurium aroA SL7207 
TBE tris borat-EDTA buffer 
TAM Tumor-associated macrophage 
Tris Tris (hydroxy methyl) aminomethane 
V Volt  
wt wildtype 
x times 
x g factor of gravity 
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